Topics

Targeted Protein Degradation

Proteostasis Multiprotein Complexes and Disease Cancer Immunotherapy

Targeted protein degradation is a therapeutic strategy that eliminates disease-associated proteins instead of only inhibiting their activity. The field has expanded rapidly because molecular glues and PROTACs can recruit cellular degradation machinery to proteins previously considered difficult to drug, including transcription factors, scaffold proteins, non-enzymatic regulators, and oncogenic fusion proteins[1][2][3].

Mechanistically, PROTACs are bifunctional molecules that bind a protein of interest and an E3 ubiquitin ligase, forming a ternary complex that drives ubiquitination and proteasomal degradation. Molecular glue degraders remodel E3 ligase surfaces or stabilize protein-protein interactions, causing neosubstrate polyubiquitination and degradation. Most clinical degraders use the ubiquitin-proteasome system, while ATTEC, AUTAC, and LYTAC approaches expand degradation toward the autophagy-lysosome pathway for long-lived proteins, aggregates, and abnormal organelles[2][4][5].

Cancer applications include degradation of androgen receptor, estrogen receptor, BTK, IKZF1/3, CDKs, BCL-xL, transcription factors, and resistance-driving oncogenic proteins. In prostate cancer cells, VNPP433-3β promoted androgen receptor degradation through interaction with MDM2, ubiquitination, and proteasomal degradation. In cancer therapy more broadly, PROTACs and molecular glues are being developed to overcome acquired resistance, widen the druggable proteome, and create next-generation precision oncology strategies[3][6][7][8].

Major gaps include oral bioavailability, pharmacokinetics, off-target degradation, resistance, linker design, E3 ligase selection, tumor delivery, limited E3-ligase diversity, and the “hook effect” at high PROTAC concentrations. Future research should expand E3 ligase toolkits, improve molecular-glue discovery, use multi-omics and AI-driven design, validate degradation biomarkers, and develop tissue-selective or lysosome-directed platforms. Targeted protein degradation therefore shifts drug discovery from occupancy-based inhibition to event-driven removal of pathogenic proteins[1][2][4][9].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Kits
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-10219 Rapamycin
Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin is a molecular glue that binds FKBP12 and mTOR proteins together, thereby inhibiting mTOR kinase activity. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant.

Source: bacterium Streptomyces hygroscopicus

mTOR   FKBP   Molecular Glues   Fungal   Autophagy   Endogenous Metabolite   Antibiotic   Bacterial  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Fungal Infection   Pain   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
1441
HY-13757 Tamoxifen Citrate
Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen Citrate activates autophagy and induces apoptosis. Tamoxifen Citrate can also be used to induce gene knockout in CreER transgenic mice.
Estrogen Receptor/ERR   HSP   Autophagy   Apoptosis  
Neurological, Eye or Ear Disease   Digestive System Disease   Prostate Cancer   Viral Infection   Digestive System Inflammation   Luminal Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Lung Fibrosis  
259
HY-13757A Tamoxifen
Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen can also be dissolved in corn oil (HY-Y1888) for use in inducing gene knockout in CreER transgenic mice. Tamoxifen has better solubility in corn oil compared to Tamoxifen Citrate (HY-13757).
Estrogen Receptor/ERR   HSP   Autophagy   Apoptosis  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease   Digestive System Disease   Prostate Cancer   Viral Infection   Digestive System Inflammation   Luminal Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Lung Fibrosis  
259
HY-50767 Palbociclib
Palbociclib (PD 0332991) is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
CDK  
Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Luminal Breast Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
249
HY-50767C Palbociclib hydrochloride
Palbociclib (PD 0332991) hydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib hydrochloride has potent anti-proliferative activity and induces cell cycle arrest in cancer cells. Palbociclib hydrochloride can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma.
CDK  
Breast Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer  
229
HY-70002 Enzalutamide
Enzalutamide (MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. Enzalutamide is an autophagy activator.
Androgen Receptor   Autophagy  
Prostate Cancer   Pancreatic Cancer   Viral Infection  
229
HY-B0579 Cyclosporin A
Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM. Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion.

Source: the fungus Beauveria nivea.

Molecular Glues   Complement System   Antibiotic   Cyclophilin  
Neurological, Eye or Ear Disease   Breast Cancer   Prostate Cancer   Viral Infection   Autoimmune Disease   SARS-CoV-2 Infection   Lung Fibrosis  
213
HY-13636 Fulvestrant
Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC50 of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC50 of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy.
Estrogen Receptor/ERR   Autophagy   Apoptosis  
Prostate Cancer   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation   Non-Small Cell Lung Cancer   Luminal Breast Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
143
HY-10997 Ibrutinib
Ibrutinib (PCI-32765) is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
Btk   Ligands for Target Protein for PROTAC  
Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Non-Small Cell Lung Cancer   SARS-CoV-2 Infection   Rheumatoid Arthritis  
136
HY-B0141 Estradiol
Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering.
Estrogen Receptor/ERR   Endogenous Metabolite   Bacterial  
Metabolic or Endocrine Disease   Prostate Cancer   Viral Infection   Bacterial Infection   Neurodegenerative Disease   Cardiovascular Disease   Luminal Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection  
136
HY-16297A Abemaciclib
Abemaciclib (LY2835219) is a selective and BBB-permeable CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively.
CDK  
Neurological, Eye or Ear Disease   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Non-Small Cell Lung Cancer   Luminal Breast Cancer   HER-2 Positive Breast Cancer   Metastatic Breast Cancer   Metastatic Prostate Cancer  
126
HY-13756A Tacrolimus monohydrate
Tacrolimus (FK506) monohydrate, a molecular glue, a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus monohydrate inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.

Source: Streptomyces tsukubaensis

Phosphatase   FKBP   Molecular Glues   Bacterial   Autophagy   Antibiotic  
Inflammation or Immune System Disease  
106
HY-13756 Tacrolimus
Tacrolimus (FK506), a molecular glue, a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.

Source: fungus Streptomyces tsukubaensis.

Phosphatase   FKBP   Molecular Glues   Bacterial   Autophagy   Antibiotic  
Inflammation or Immune System Disease  
106
HY-15484 Pifithrin-α hydrobromide
Pifithrin-α hydrobromide is a p53 inhibitor which blocks its transcriptional activity and prevents cells from apoptosis. Pifithrin-α hydrobromide is also an aryl hydrocarbon receptor (AhR) agonist.
MDM-2/p53   Aryl Hydrocarbon Receptor   Ferroptosis   Apoptosis  
Lung Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Digestive System Inflammation  
102
HY-L025 Anti-Cancer Compound Library
Cancer is the second leading cause of death globally and seriously threatens human health. A neoplasm and malignant tumor are other common names for cancer. Disruption of the normal regulation of cell-cycle progression and division lies at the heart of the events leading to cancer. Target therapy, which targets proteins that control how cancer cells grow, divide and spread, plays an important role in cancer treatment. Recent studies mainly focus on targeting the key proteins for cancer surviving, cancer stem cells, the tumor microenvironment, tumor immunology, etc. MCE designs a unique collection of 11,167 anti-cancer compounds that target kinases, cell cycle key components, tumorigenesis related signaling pathways, etc. MCE Anti-cancer compound library is a useful tool for anti-cancer drug screening.

Disease Focused Libraries

99
HY-N0322 Cholesterol (from animal)
Cholesterol (from animal) is the major sterol in mammals. It is making up 20-25% of structural component of the plasma membrane. Plasma membranes are highly permeable to water but relatively impermeable to ions and protons. Cholesterol (from animal) plays an important role in determining the fluidity and permeability characteristics of the membrane as well as the function of both the transporters and signaling proteins. Cholesterol (from animal) is also an endogenous estrogen-related receptor α (ERRα) agonist.
Environmental Pollutants   Bacterial   Estrogen Receptor/ERR   Endogenous Metabolite   Liposome  
Breast Cancer   Viral Infection   Bacterial Infection   Pancreatic Ductal Adenocarcinoma   Hepatitis B Virus Infection   Alzheimer's Disease   Sepsis   Atherosclerosis   Type 2 Diabetes   Obesity   Hypercholesterolemia  
92
HY-L031 Small Molecule Immuno-Oncology Compound Library
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines. MCE Small Molecule Immuno-Oncology Compound Library offers 813 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

Disease Focused Libraries

88
HY-14590 Kaempferol
Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer.
Estrogen Receptor/ERR   Autophagy   Mitophagy   Apoptosis   HIV   Parasite   Endogenous Metabolite  
Digestive System Disease   Lung Cancer   Breast Cancer   Ovarian Cancer   Viral Infection   Parasitic Infection   Digestive System Inflammation   Glucose Metabolism  
85
HY-L077 Anti-Pancreatic Cancer Compound Library
Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer. MCE offers a unique collection of 4,277 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

Disease Focused Libraries

85
HY-15777 Ribociclib
RRibociclib (LEE011) is an ATP-competitive and orally active CDK4/6 inhibitor that crosses the blood-brain barrier with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex.
CDK  
Neurological, Eye or Ear Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Non-Small Cell Lung Cancer   Luminal Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
84
HY-L023 Toxins for Antibody-Drug Conjugate Research Library
Antibody-Drug Conjugates (ADCs), a new class of treatment for cancer, are composed with a monoclonal antibody, a linker and a cytotoxic agent also referred to as a payload. To date, several ADCs have received market approval and more than 60 ADCs are currently in clinical trials. ADCs are one of the fastest growing classes of oncology drugs worldwide. The payload or cytotoxic agent is the most important unit in the ADC. ADC has the capability to kill cancer cell depending on the potency of the payload. MCE provides 118 highly potent cytotoxins that contain auristatin derivatives, maytansinoids, calicheamicin, duocarmycin, pyrrolobenzodiazepines (PBDs), etc.

Compound Characteristic Classified Libraries

84
HY-L050 Ubiquitination Compound Library
Protein ubiquitination is an enzymatic post-translational modification in which an ubiquitin protein is attached to a substrate protein. Ubiquitination involves three main steps: activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), and ubiquitin ligases (E3s), respectively. Ubiquitination affects cellular processes such as apoptosis, cell cycle, DNA damage repair, and membrane transportation, etc. by regulating the degradation of proteins (via the proteasome and lysosome), altering the cellular localization of proteins, affecting proteins activity, and promoting or preventing protein-protein interactions. Deregulation of ubiquitin pathway leads to many diseases such as neurodegeneration, cancer, infection and immunity, etc. MCE offers a unique collection of 494 small molecule modulators with biological activity used for ubiquitination research. Compounds in this library target the key enzymes in ubiquitin pathway. MCE Ubiquitination Compound Library is a useful tool for the research of ubiquitination regulation and the corresponding diseases.

Signaling Pathway Targeting Libraries

84
HY-L075 Anti-Lung Cancer Compound Library
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 3,012 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Disease Focused Libraries

84
HY-L080 Targeted Therapy Drug Library
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer by interfering with specific molecular targets that are involved in the growth, progression, and spread of cancer. There are several different types of targeted therapy. The most common types are small-molecule drugs and monoclonal antibodies. Small-molecule drugs are small enough to enter cells easily, so they are used for targets that are inside cells, while monoclonal antibodies are usually used for targets that are located outside the cells. Because of high specificity, low side effect and potent anticancer activity, targeted therapy has become the mainstream of new anti-tumor drugs. Various targeted therapies have been approved by FDA and used in the treatment of diseases. MCE carefully collects a unique of 108 targeted therapy drugs used in cancer treatment. MCE Targeted therapy drug library is a useful tool for the research of targeted therapy.

Disease Focused Libraries

84
HY-L151 PROTAC Library
PROTACs (Proteolysis-targeting chimeras) is a class of molecules that utilize ubiquitin-proteasome system (UPS) to ubiquitinate and degrade target proteins. The PROTACs molecule consists of two ligands joined by a linker. The one-to-one interaction between PROTACs and target proteins determines the high efficiency of PROTACs, making it a potential molecule for targeted protein degradation (TPD) therapy. MCE supplies a unique collection of 530 PROTACs that effectively degrade target proteins with more powerful screening capability. MCE PROTAC Library is a useful tool for signal pathway research, protein degradation therapy research, drug discovery and drug repurposing, etc.

Compound Characteristic Classified Libraries

84
HY-L188 Anti-Brain Cancer Compound Library
Although brain cancer only accounts for 2% of all tumors, it has a poor prognosis, high mortality and high recurrence rate. Brain cancer can be divided into primary brain cancer and secondary brain cancer. According to the location of the cancer, brain cancer can also be divided into: brain glioma, pituitary adenoma, schwannoma, craniopharyngioma, meningioma and so on. Glioma is the most common primary brain tumor, accounting for about 1/3 of all brain tumors. At present, brain cancer lacks precision targeted therapeutic drugs, and there is still a great clinical demand that has not been met. With the continuous development of high-throughput screening technology, it may be able to help develop effective anti-brain cancer drugs by screening compounds targeting PKC, PD-1, c-Met, PARP, etc targets. MCE designs a unique collection of 2,113 small molecules with definite or potential anti-brain cancer activity, which is an important tool for studying the pathological mechanism of brain cancer and developing drugs for brain cancer.
84
HY-14660 Dabrafenib
Dabrafenib (GSK2118436A) is an ATP-competitive inhibitor of Raf with IC50s of 5 nM and 0.6 nM for C-Raf and B-RafV600E, respectively.
Raf   CDK  
Colorectal Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Non-Small Cell Lung Cancer  
83
HY-L041 Macrocyclic Compound Library
Macrocycles, molecules containing 12-membered or larger rings, are receiving increased attention in small-molecule drug discovery. The reasons are several, including providing access to novel chemical space, challenging new protein targets, showing favorable ADME- and PK-properties. Macrocycles have demonstrated repeated success when addressing targets that have proved to be highly challenging for standard small-molecule drug discovery, especially in modulating macromolecular processes such as protein–protein interactions (PPI). Otherwise, the size and complexity of macrocyclic compounds make possible to ensure numerous and spatially distributed binding interactions, thereby increasing both binding affinity and selectivity. MCE offers a unique collection of 464 macrocyclic compounds which can be used for drug discovery for high throughput screening (HTS) and high content screening (HCS). MCE Macrocyclic Compound Library is a useful tool for discovering new drugs, especially for “undruggable” targets and protein–protein interactions.

Structure Classified Libraries

83
HY-L045 Oxygen Sensing Compound Library
Oxygen homeostasis regulation is the most fundamental cellular process for adjusting physiological oxygen variations, and its irregularity leads to various human diseases, including cancer. Hypoxia is closely associated with cancer development, and hypoxia/oxygen-sensing signaling plays critical roles in the modulation of cancer progression. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that functions as a master regulator of oxygen homeostasis. A variety of HF-1 target genes have been identified thus far which encode proteins that play key roles in critical developmental and physiological processes including angiogenesis/vascular remodeling, erythropoiesis, glucose transport, glycolysis, iron transport, and cell proliferation/survival. HIF-1 is a heterodimeric transcription factor consisting of a constitutively expressed β-subunit and an oxygen-regulated α-subunit. The unique feature of HIF-1 is the regulation of HIF-1α expression and activity based upon the cellular O2 concentration. Under normoxic conditions, hydroxylation of HIF-1α on these different proline residues is essential for HIF proteolytic degradation by promoting interaction with the von Hippel-Lindau tumor-suppressor protein (pVHL) through hydrogen bonding to the hydroxyproline-binding pocket in the pVHL β-domain. As oxygen levels decrease, hydroxylation of HIF decreases; HIF-1α then no longer binds pVHL, and becomes stabilized, allowing more of the protein to translocate to the cell’s nucleus, where it acts as a transcription factor, upregulating (often within minutes) the production of proteins that stimulate blood perfusion in tissues and thus tissue oxygenation. MCE offers a unique collection of 4,246 oxygen sensing related compounds targeting HIF/HIF Prolyl-Hydroxylase, MAPK/ERK, PI3K/AKT signaling pathways, etc. MCE Oxygen Sensing Compound Library is a useful tool to study hypoxia, oxidative stress and discover new anti-cancer drugs.

Signaling Pathway Targeting Libraries

83
HY-L074 Anti-Breast Cancer Compound Library
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 3,365 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Disease Focused Libraries

83
HY-L079 Anti-Blood Cancer Compound Library
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly. Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed. MCE offers a unique collection of 4,276 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.

Disease Focused Libraries

83
HY-L128 E3 Ligase Ligand Library
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2). MCE carefully prepared a unique collection of 181 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

Compound Characteristic Classified Libraries

83
HY-L129 Target Protein Ligand Library
Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation. Therefore, PROTACs execute their functions by degrading the target proteins rather than inhibiting them, which has a great superiority in overcoming resistance caused by target mutation or overexpression. To date, PROTAC technology has been applied to a variety of targets, including AR, ER, BTK, BET, and BCR-ABL to overcome resistance. MCE carefully prepared a unique collection of 123 ligands for target proteins, which have been reported to be used in PROTAC design. MCE Target Protein Ligand Library is a useful tool for PROTAC development.

Compound Characteristic Classified Libraries

83
HY-L135 Cancer Stem Cells Compound Library
With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on. Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment. MCE supplies a unique collection of 3,499 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

Compound Characteristic Classified Libraries

83
HY-L137 Molecular Glue Compound Library
Targeted protein degradation(TPD) is a novel and promising approach to new drug discovery and development. It shows great potential for treating diseases with “undruggable” pathogenic protein targets and for overcoming drug resistance. Molecular glues and PROTACs are both targeted protein degraders that have attracted the most attention. Molecular glues are small molecular degraders that mainly induce novel interaction between an E3 ligase and a target protein to form a ternary complex, leading to protein ubiquitination and subsequent proteasome degradation. Compared with PROTACs, molecular glues generally possess more favorable drug-like properties, such as lower MW, higher cell permeability, and better oral absorption. Molecular glues are emerging as a promising new therapeutic strategy. MCE supplies a unique collection of 114 molecular glues which target various proteins. MCE Molecular Glue Compound Library is a useful tool to conduct scientific research and disease mechanism study.

Compound Characteristic Classified Libraries

83
HY-L184 Anti-Gastric Cancer Compound Library
Gastric Cancer (GC) is one of the most common malignant tumors in the world, ranking fourth in mortality rate globally. Because the early symptoms of stomach neoplasm are usually not obvious, are diagnosed with gastric cancer at terminal stage, and the relative survival rate within 5 years is very low. With the further understanding of the molecular characteristics of stomach neoplasm, many therapeutic targets for gastric cancer have been identified, and molecular targeted therapies such as CTLA-4, HER2 and immune checkpoint inhibitors have made rapid progress. Although survival rates for patients with gastric neoplasm have improved over the past few decades, the prognosis is still worrying. Therefore, there is an urgent need for new drugs to treat gastric cancer. MCE designs a unique collection of 1,181 small molecules with definite or potential anti-gastric cancer activity, which is an important tool for studying the pathological mechanism of stomach neoplasm and developing drugs for stomach neoplasm.

Disease Focused Libraries

83
HY-L213 Anti-Cancer Approved Drug Library
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies. This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment. MCE has collected 268 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
83
HY-L214 Liposome Library
Liposomes are spherical or multilayered spherical vesicles formed by the self-assembly of diacyl chain phospholipids (lipid bilayers) in aqueous solutions, which can be made from natural or synthetic phospholipids and exhibit good biocompatibility and low toxicity. They can serve as delivery carriers for various bioactive substances (such as drugs, proteins, nucleic acids, etc.) and are widely used in biomedical and chemical research. The main advantages of liposomes include 1) Protective effect: Their bilayer structure can protect encapsulated molecules from enzymatic degradation, oxidation, and other influences, extending stability and activity; 2) Active targeting: Surface modifications enable active targeting, enhancing the concentration of drugs or molecules in specific tissues or cells; 3) Customizability: The composition and structure of liposomes can be adjusted according to needs, such as altering phospholipid types or adding targeting ligands. These properties make liposomes highly valuable in developing novel drug delivery systems, serving as nucleic acid carriers for gene transfection, studying cellular uptake mechanisms and drug release kinetics, as well as developing functional food additives to improve the bioavailability of nutritional components. MCE contains 192 liposome compounds, which is a good tool for drug delivery-related studies.
83
HY-L216 Polysaccharides Compound Library
Polysaccharides are long chains of carbohydrate molecules, consisting of multiple smaller monosaccharides. Polysaccharides are found mainly in natural sources such as plants, microorganisms, algae and animals. Polysaccharides have a large number of active functional groups, different chemical compositions and different molecular weight ranges, which determines their diversity in nature and structure. Also in the field of medical research, polysaccharides act as a class of functional compounds and thus play a role. For example, nanocarrier construction, immunomodulation and vaccine development, new strategies for antitumor therapy, tissue regeneration engineering applications and disease diagnosis. With the advancement of glycomics and synthetic biotechnology, human beings are moving from “knowing polysaccharides” to “designing polysaccharides”, which will provide innovative solutions for materials science, precision medicine and sustainable development. MCE offers 70 polysaccharides that can be used in biomedical studies.
83
HY-L222 PROTAC Linkers Library
Linkers play a necessary role in the physicochemical properties and biological activity of the bifunctional molecule. These linkers are not a simply connection of two functional modules together, but its design and nature directly affect the stability, activity, selectivity, pharmacokinetics, and ultimately the therapeutic efficacy of the entire molecule. The length of the linker determines the extent of interaction between the two ligands and thus the maximum activity of the PROTAC molecule. MCE has collected 0 PROTAC Linkers can be used for the design and synthesis of bifunctional molecules.
83
HY-L248 RNA Binding Bioactive Compound Library
The RNA-targeted bioactive compound library is a high-quality collection of small molecules specifically designed and curated to target RNA structures and functions. It is widely applied in cutting-edge drug discovery and life science research. Unlike traditional strategies that focus on protein targets, RNA-targeted compounds can directly modulate various functional RNA molecules by influencing their splicing, translation, stability, or structural conformation, thereby enabling precise intervention in key biological processes. In the field of drug development, these compounds provide a novel approach to addressing previously “undruggable” targets and have demonstrated significant potential in areas such as oncology, antiviral therapies, and neurodegenerative diseases. For example, by targeting disease-associated RNA structural domains or regulating the aberrant expression of non-coding RNAs, these compounds can effectively inhibit disease progression or restore normal cellular function. In mechanistic studies, RNA-targeted compounds serve as valuable chemical biology tools to elucidate the roles of RNA in gene expression regulation, cellular signaling pathways, and disease development. The MCE RNA-targeted bioactive compound library contains 860 compounds, sourced from databases such as TargetRX Atlas and R-BIND. The library features excellent structural diversity and biological activity, making it suitable for high-throughput screening (HTS), target validation, phenotypic screening, and lead compound discovery. It represents a valuable resource for RNA-related research and innovative drug development.

Signaling Pathway Targeting Libraries

83
HY-L250 Lactic Acid Metabolite Compound Library
In the progression of various diseases, metabolic reprogramming has emerged as a key hallmark. Lactate, as an important metabolic signaling molecule, is widely involved in tumorigenesis, immune regulation, and inflammatory responses. Particularly within the tumor microenvironment, the abnormal accumulation of lactate not only affects cellular energy metabolism but also promotes disease progression by modulating immune cell functions and mediating protein lactylation, thereby participating in epigenetic regulation and signaling networks. Therefore, systematic investigation of lactate metabolic pathways and their associated metabolites is of great significance for understanding disease mechanisms and developing novel therapeutic strategies. The MCE lactic acid metabolite compound library contains 61 compounds and is constructed around key metabolic pathways involving lactate production, transport, and utilization. This library systematically includes core intermediates from glycolysis, the tricarboxylic acid (TCA) cycle, and the lactate cycle. Focusing on disease-associated metabolic reprogramming, it is suitable for research in oncology, inflammation, and metabolic disorders. The library can be used to elucidate the roles of lactate in tumor microenvironment regulation, immune evasion, and epigenetic modifications (such as protein lactylation). In addition, it provides high-quality small-molecule resources for drug screening, facilitating the discovery of potential modulators targeting key enzymes (such as LDH) or transporters (such as MCTs) involved in lactate metabolism.

Signaling Pathway Targeting Libraries

83
HY-L252 Carbohydrate Metabolite Compound Library
Carbohydrate metabolism serves as a central hub for energy supply and biosynthesis in living organisms and plays a critical role in the onset and progression of various diseases. In recent years, studies have shown that tumor cells reprogram their energy metabolism through aerobic glycolysis (the Warburg effect) to support rapid proliferation. Immune cells also rely on specific carbohydrate metabolic pathways to regulate their activation and differentiation states, while disorders such as diabetes and metabolic syndrome arise directly from dysregulation of carbohydrate metabolism. In addition, enzymes and key metabolic nodes involved in carbohydrate metabolism have become important targets for drug discovery, and therapeutic strategies targeting glycolysis, the pentose phosphate pathway, and energy metabolism are continuously advancing the treatment of cancer and metabolic diseases. Therefore, systematic analysis of carbohydrate metabolic networks and their associated metabolites is of great significance for elucidating disease mechanisms and developing novel therapeutic approaches. The MCE Carbohydrate Metabolism Metabolite Library is constructed based on classical carbohydrate metabolic pathways and contains 75 metabolites. It systematically integrates key metabolic networks, including glycolysis, the pentose phosphate pathway, the tricarboxylic acid (TCA) cycle, monosaccharide metabolism, and sugar acid interconversions. The library comprehensively covers core metabolic nodes from glucose uptake and utilization to energy production and biosynthesis, while also incorporating important upstream and downstream intermediates. It enables accurate representation of intracellular metabolic flux dynamics and is well suited for applications such as metabolic flux analysis, target validation, and mechanistic studies. Furthermore, it provides robust support for multi-omics integration and the development of precision intervention strategies.
83
HY-L256 Azide Compound Library
In modern drug discovery and chemical biology research, the azide group (-N3) is an important functional moiety that is widely used in click chemistry, biomolecular labeling, drug delivery systems, and prodrug design due to its unique reactivity and bioorthogonality. The MCE Azide Structural Compound Library contains 96 compounds featuring -N3 functional groups. It is designed for the construction of click chemistry reaction systems and the subsequent development of functional molecules. This library enables the rapid assembly of targeting ligands, linkers, and functional molecular modules, thereby accelerating PROTAC assembly, optimization of antibody-drug conjugate (ADC) linkers, and the development of biological labeling probes. In addition, the high reaction selectivity and excellent biocompatibility of the azide group allow it to maintain stable reactivity even in complex biological environments, improving controllability and efficiency in drug design. It serves as an indispensable molecular tool in modern medicinal chemistry and chemical biology research.
83
HY-L258 Alkyne Compound Library
In modern medicinal chemistry and chemical biology research, alkyne (-C≡C-) structures play an important role in click chemistry, bioorthogonal labeling, and the construction of functional molecules due to their unique linear geometry and high reactivity. In particular, driven by the development of copper-catalyzed azide-alkyne cycloaddition (CuAAC) and copper-free click reactions (SPAAC), terminal alkyne groups have become important “chemical handles” for building complex biomolecular systems. The MCE Alkyne Compound Library contains 432 compounds designed for the construction of click chemistry reaction systems and the development of diverse functional molecules. In drug discovery, these structures serve as key reactive sites that can efficiently undergo click reactions with azide groups, enabling modular assembly of PROTAC molecules, construction of ADC linkers, and rapid synthesis of bioorthogonal labeling probes. In addition, alkyne groups exhibit high stability, mild reaction conditions, and excellent biocompatibility, allowing them to maintain reactivity in complex biological environments. This contributes to improved efficiency and controllability in drug development, making them indispensable chemical building blocks in modern drug design and functional molecular engineering.
83
HY-L260 KRAS Targeted Compound Library
KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is one of the most important oncogenic driver genes in oncology, with high mutation frequencies in pancreatic cancer, non‑small cell lung cancer, and colorectal cancer. For a long time, KRAS was considered "undruggable" due to the lack of suitable small‑molecule binding pockets on its protein surface. In recent years, with the discovery of the switch‑II pocket and the successful approval of KRAS G12C inhibitors, KRAS‑targeted research has achieved groundbreaking progress, which has also spurred a wave of development targeting non‑G12C mutants such as G12D and G12V, as well as upstream and downstream regulatory factors including SOS1 and SHP2. MCE KRAS Targeted Compound Library contains 79 small‑molecule compounds targeting the KRAS, serving as high‑quality research tools for mechanistic studies of KRAS‑mutant tumors, combination therapy development, resistance mechanism exploration, and high‑throughput drug screening, thereby providing robust support for KRAS‑targeted drug discovery.

Signaling Pathway Targeting Libraries

83
HY-L261 Classic FDA-Approved Drug Library
MCE Classic FDA-Approved Drug Library features a curated selection of marketed drugs that have achieved the highest prescription volumes and greatest clinical impact in global practice since 2006. The collection covers eight major therapeutic areas, including cardiovascular diseases, oncology, metabolic disorders, infectious diseases, central nervous system disorders, respiratory diseases, digestive system diseases, and immunological conditions. All compounds have been validated through long‑term clinical use and possess well‑defined molecular targets, well‑established pharmacokinetic properties, quantifiable efficacy endpoints, and comprehensive toxicological safety profiles. The library currently contains 169 representative drugs and is designed to serve as an efficient tool for drug repurposing, phenotypic screening, mechanism‑of‑action studies, and combination therapy strategy development.
83
HY-L918 Molecular Glue-like Compound Library
Targeted Protein Degradation (TPD) is a novel and promising approach to drug development. It shows great potential for targeting proteins traditionally considered "undruggable" due to the lack of enzymatic function and absence of binding sites by tagging them for degradation or recruiting natural degradation mechanisms. Molecular glues are a type of small-molecule degraders that primarily induce novel interactions between E3 ubiquitin ligases and target proteins, forming ternary complexes that lead to protein ubiquitination and subsequent proteasomal degradation. Compared with PROTACs, molecular glues generally have lower molecular weights, higher cell permeability, and better drug-like properties. Additionally, the design of molecular glues is relatively simple, without the requirements for complex linkers and ligand optimization. As a result, molecular glues have gradually emerged as a promising therapeutic approach for various diseases. Multiple types of molecular glues have been reported previously. Analysis of co-crystal complex structures reveals that CRBN-related molecular glues are more versatile. Therefore, MCE researchers select active molecules related to these targets as probes for artificial intelligence (AI) screening.Subsequently, molecular docking technology was used to verify whether the screened molecules retained the key pharmacophore features. Ultimately, we obtained 317 molecular glue analogs, and these compounds serve as powerful tools for the research of molecular glues.

Focused and target libraries

83
HY-L934 CRBN Ligand Library
CRBN, namely cereblon, is the substrate recognition subunit of the E3 ubiquitin ligase complex in the ubiquitin-proteasome system. A CRBN ligand library refers to a collection of numerous fragments that can specifically bind to the CRBN protein. These ligands are mostly designed based on validated CRBN-binding warheads and modified through AI-driven molecular generation optimization systems. They not only include classic lenalidomide-derived structures but also cover novel non-lenalidomide scaffolds. After drug-likeness filtering, these ligands exhibit structural diversity and favorable druggable properties. They can be further optimized and modified to facilitate the development of novel molecular glue degraders, accelerate the discovery of molecular glues that induce interactions between CRBN and new substrate proteins, and enable the exploration of novel CRBN substrates for identifying previously unknown CRBN-binding proteins. MCE compiles 122 fragments that can specifically bind to the CRBN protein, with molecular weights ranging from 200 to 500. Compounds developed based on the library ligands target multiple disease targets such as cancer and autoimmune diseases, further advancing the development of Molecular Glues and PROTACs therapeutic agents.

Featured Fragment Libraries

83
HY-L935 Molecular Glue POI binding Fragment library
POI (Protein of Interest) refers to the target protein, namely the disease-causing protein or key functional protein that undergoes degradation or functional modulation in molecular glue-mediated processes. The Molecular Glue POI Library consists of a series of fragments that can specifically bind to different types of POIs. As key components of molecular glues, these ligands form stable interactions with target proteins, laying the foundation for molecular glues to induce the interaction between POIs and E3 ubiquitin ligases. The covered POIs include various types such as cancer-associated GSPT1, androgen receptors, and abnormally aggregated proteins linked to neurodegenerative diseases. This fragment library can be applied to the screening and optimization of targeted protein degraders. By screening ligands with high affinity and strong selectivity for specific POIs from the library, core structures can be identified to develop novel molecular glues. For instance, optimization of ligands targeting GSPT1 has yielded molecular glue degraders with enhanced degradation activity. Since many POIs are difficult to drug due to the lack of traditional small-molecule binding pockets, some ligands in the POI Ligand Library can modulate such POIs by inducing protein-protein interactions, thereby further expanding the scope of drug discovery for undruggable targets. MCE has compiled a POI Fragment Library comprising thousands of POI fragments with molecular weights ranging from 150 to 400. This compound library can be widely applied in Molecular Glue research and development.

Featured Fragment Libraries

83
HY-L936V0 Molecular Glue Virtual Library
Molecular Glue Virtual Library is constructed using generative AI technology, integrating the structural features, activity data of known molecular glues, and interaction information of ternary complexes (target protein-E3-molecular glue). Endowed with structural novelty, drug-likeness, diversity and synthesizability, it is applicable to molecular glue-based AI drug screening and large-scale virtual screening. MCE builds this library based on high-quality molecular building blocks by virtue of robust computing power, coupled with rigorous reaction rules and optimized compound generation strategies. To ensure library quality, molecules with high synthetic difficulty, poor drug-likeness, PAINS and other undesirable molecules are excluded first. Subsequently, scaffold-based compound analysis is performed to screen drug-like diverse molecules for synthesizability evaluation; those with excessively high synthetic difficulty are removed, ultimately forming a large-scale molecular glue virtual library with structural diversity, synthesizability and drug-likeness. Compounds in the library can be synthesized in only 1-2 chemical reaction steps. With MCE’s experienced chemical synthesis team, custom synthesis of different scales from milligram to kilogram can be easily achieved to meet diverse customer needs.

AI-enabled Libraries

83
HY-L944 MCE‑18 Novelty Focused Drug‑Like Library
MCE 18 stands for Medicinal Chemistry Evolution 2018. This metric was established based on structural data of 28,161 patented lead molecules, 1,370 marketed innovative drugs, and nearly 30,000 investigational candidates from preclinical to Phase III stages across 23 major global pharmaceutical companies from 1950 to 2018. After scaffold clustering analysis, a scoring model was constructed by integrating five three dimensional scaffold characteristics, including aromatic rings (AR), non aromatic heterocycles (NAR), chiral centers (CHIRAL), spirocycles (SPIRO), and the sp³ carbon ratio in cyclic and acyclic moieties, enabling quantitative assessment of molecular scaffold novelty and three dimensional complexity. According to the score distribution of patented molecules, the top 25% of the original patent dataset was defined as the high novelty region. MCE 18 high scoring compounds selected based on this criterion can effectively avoid scaffold patent conflicts and intellectual property risks from the source. Molecules in this range typically feature a high sp³ carbon ratio, abundant chiral centers, spirocycles, and fused heterocycles with prominent three dimensional conformations. Their spatial properties allow precise matching to complex non traditional undruggable target pockets such as PPI interfaces and allosteric sites, making them ideal structural types for early stage screening of First in class drugs. MCE‑18 Novelty Focused drug‑Like library strictly selects molecules from the aforementioned high scoring range, containing more than 10,000 premium drug like molecules with highly diverse scaffolds and rich 3D diversity. It can be used for high throughput screening of well established targets such as kinases, GPCRs, and proteases, and is especially suitable for hit identification in allosteric modulation, protein–protein interactions, and various undruggable orphan targets, fully supporting early stage drug discovery for cutting edge innovat

Distinctive Diversity Libraries

83
HY-L945 Sulfonyl Fluoride Fragment Library
Sulfonyl fluoride (-SO₂F) overcomes the poor target selectivity of traditional covalent warheads that rely heavily on cysteine. With high stability and tunable electrophilicity under physiological conditions, it targets multiple nucleophilic residues including Lys, Tyr, Ser and His, offering expanded druggable space, lower off-target risks and prolonged efficacy. It is widely used in covalent inhibitors, molecular glues, PROTACs and chemical probes. MCE has built a highly diverse sulfonyl fluoride fragment library with 1,162 structurally diverse, drug-like fragments. Designed for balanced reactivity, stability and compatibility, these molecules feature tunable electrophilicity, simple scaffolds and high derivatization potential. Combined with SuFEx click chemistry, the library enables efficient modular modification and rapid structure optimization. Ideal for targeting non-cysteine residues, this library improves covalent screening and probe development efficiency, serving as a precise tool for early-stage covalent drug discovery and chemical biology research.

According to Fragment Structures

83
HY-L949 Spirocyclic Privileged Scaffold Lead-like Library
Spirocyclic compounds, with rigid 3D structures, high Fsp³ and strong conformational restriction, are highly privileged scaffolds in small-molecule drug screening. They overcome drawbacks of planar aromatic compounds such as poor solubility, high off-target risks and weak druggability. Their orthogonal bicyclic geometry fits well into protein pockets, improving target affinity, subtype selectivity, metabolic stability and membrane permeability, making them ideal for hit identification against kinases, GPCRs, PPIs and other targets. Spirocyclic scaffolds have been widely applied in oncology, antivirals, hypertension and CNS diseases, leading to many approved drugs and clinical candidates. SAR studies show that spiro-atom chirality, ring size and heteroatom substitution dominate bioactivity and selectivity, with the scaffold mainly serving as a conformational anchor. Azaspirocycles, spirooxindoles and spirosteranes target GPCRs, kinases, MDM2-p53 and PPIs. Approved drugs including irbesartan, spironolactone and rolapitant confirm their druggability, while revumenib and SAR405838 show promise against undruggable targets. The MCE Spirocyclic Druglike Library contains over 1,000 diverse, stereospecific molecules selected by Lipinski’s rules. It covers privileged cores such as azaspirocycles, oxaspirocycles and spirooxindoles. These molecules bear rich chiral centers and distinct 3D orientations, reducing non-specific binding and enhancing screening efficiency. Featuring novel scaffolds, the library offers a highly innovative starting point for drug discovery.

According to Lead-like Structures

83
HY-L950 7-Membered Ring Privileged Scaffold Lead-like Library
Seven-membered rings are privileged medium-sized scaffolds with distinct twist-chair conformations and greater 3D diversity than five- and six-membered rings. Their flexible conformations allow induced-fit protein binding and precise pharmacophore positioning. They also modulate Fsp³, pKa and logP to enhance solubility and permeability. Azepanes, oxepanes and benzodiazepines serve as bioisosteres for hit discovery against GPCRs, ion channels and kinases. Widely found in plant and microbial alkaloids, seven-membered heterocycles show excellent biocompatibility and target affinity. They underpin many approved drugs for CNS, cancer and infectious diseases, including diazepam, imipramine and carbamazepine. Clinical candidates further highlight their unique value. However, high transannular strain and synthetic difficulty limit their availability, leaving them rare in standard screening libraries. MCE 7 Membered Scaffold Library contains 2,792 structurally diverse, lead-like molecules covering azepanes, oxepanes, benzodiazepines and dibenzazepines. With varied substitutions, chiral centers and synthetic accessibility, it fills the shortage of medium-ring scaffolds. Ideal for HTS, virtual screening and SAR studies, these novel, patent-clear compounds offer a distinctive starting point for drug discovery in CNS disorders, oncology, antivirals and challenging targets such as PPIs.

According to Lead-like Structures

83
HY-LD004 DEL Covalent Library
DEL technology enables the simultaneous screening of millions or billions of compounds in a single tube by covalently linking each small molecule with a unique DNA sequence. Traditional DEL screening primarily focuses on identifying non-covalent binding molecules, where interactions with the target are reversible. In contrast, DNA‑encoded covalent library is an ultra‑high‑throughput screening library developed on the basis of conventional DNA‑encoded library technology. It incorporates controllable electrophilic covalent warheads capable of forming irreversible covalent bonds with amino acid residues at the active sites of target proteins, including Cys, Lys, Ser, Tyr, and others. This covalent binding enhances binding affinity, prolongs residence time at the target site, and has the potential to overcome challenges associated with traditional non-covalent inhibitors, such as drug resistance or off-target effects. Each compound in the library contains both a binding domain and an electrophilic warhead. It first recognizes and binds to the target through non covalent interactions, and then forms a stable covalent bond with key amino acid residues to achieve irreversible inhibition. This library is specifically designed for the discovery of potent, long lasting, and highly selective covalent inhibitors, particularly for undruggable targets such as kinases, GPCRs, proteases, and mutant oncoproteins. Each molecule is uniquely labeled with a DNA barcode for molecular identification and sequencing decoding. This library is an advanced and highly diverse collection, consists of 35 independent sub-libraries with a total scaleof 14 million compounds, It incorporates over 14 experimentally validated covalent warheads capable of targeting cysteine, lysine, arginine, aspartic acid and glutamic acid. This library is constructed with diverse drug like core scaffolds and integrated controllable covalent warheads, it features structural diversity, reaction spec

DNA Encoded Libraries

83
HY-LD005 DEL D Kit Cyclic Peptide Library
Cyclic peptide library have advantages such as high affinity, high selectivity, and suitability for targeting protein–protein interactions. Through DEL synthesis technology, the library size can achieve hundreds of millions. DEL cyclic peptide library have advantages like low cost andhigh screeing efficiency, making them valuable for discovering lead compounds against challenging drug targets. This cyclic peptide library is constructed with unnatural amino acids as building block, synthesized through DNA-compatible chemical reactions. Each cyclic peptide consist of six amino acids and constrained conformations such as side-chain cross-linking, disulfide bonds, and macrocyclization. These cyclic peptides exhibit significantly improved stability and druggability compared with linear peptides, filling the gap between small molecules and macromolecular biologics. Each cyclic peptide is uniquely conjugated to a DNA barcode sequence for molecular identification and sequencing decoding. MCE’s cyclic peptide library has8 independent sub-libraries, with a total molecular diversity of 1.2 billion. It is constructed via multi-round combinatorial assembly of building blocks and diverse cyclization strategies, facilitating the discovery of cyclic peptide leads for undruggable targets.

DNA Encoded Libraries

83
HY-10029 Nutlin-3a
Nutlin-3a (Rebemadlin), an active enantiomer of Nutlin-3, is a potent murine double minute (MDM2) inhibitor (IC50=90 nM). Nutlin-3a inhibits MDM2-p53 interactions and stabilizes the p53 protein, and induces cell autophagy and apoptosis. Nutlin-3a has the potential for the study of TP53 wild-type ovarian carcinomas.
MDM-2/p53   E1/E2/E3 Enzyme   Autophagy   Apoptosis  
Colorectal Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation  
74
HY-12529 Ro-3306
Ro-3306 is a potent and selective inhibitor of CDK1, with Kis of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.
CDK   Apoptosis  
Digestive System Disease   Breast Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
74
HY-17412 Minocycline hydrochloride
Minocycline hydrochloride is an orally active, potent and BBB-penetrated semi-synthetic tetracycline antibiotic. Minocycline hydrochloride is a hypoxia-inducible factor (HIF)-1α inhibitor. Minocycline hydrochloride shows anti-cancer, anti-inflammatory, and glutamate antagonist effects. Minocycline hydrochloride reduces glutamate neurotransmission and shows neuroprotective properties and antidepressant effects. Minocycline hydrochloride inhibits bacterial protein synthesis through binding with the 30S subunit of the bacterial ribosome, resulting in a bacteriostatic effect.
Bacterial   Antibiotic   HIF/HIF Prolyl-Hydroxylase   Apoptosis   MDM-2/p53   Potassium Channel   Calcium Channel  
Metabolic or Endocrine Disease   Breast Cancer   Colorectal Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Depression   Digestive System Inflammation   Cardiovascular Disease   SARS-CoV-2 Infection   Lung Fibrosis  
72
HY-A0003 Lenalidomide
Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
Ligands for E3 Ligase   Molecular Glues   Apoptosis  
Neurological, Eye or Ear Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection  
63
HY-14650 DHEA
DHEA (Prasterone) is one of the most abundant steroid hormones. DHEA (Prasterone) mediates its action via multiple signaling pathways involving specific membrane receptors and via transformation into androgen and estrogen derivatives (e.g., androgens, estrogens, 7α and 7β DHEA, and 7α and 7β epiandrosterone derivatives) acting through their specific receptors.
Environmental Pollutants   Androgen Receptor   Endogenous Metabolite  
Digestive System Disease   Breast Cancer   Prostate Cancer   HIV Infection   Depression   Digestive System Inflammation   Cardiovascular Disease   SARS-CoV-2 Infection   Type 1 Diabetes   Crohn's Disease   Lupus Erythematosus   Osteoporosis  
59
HY-16950 4-Hydroxytamoxifen
4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally active, selective estrogen receptor modulator (SERM). 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is also the active metabolic form of Tamoxifen (HY-13757A) in vivo and can be used to induce gene knockout in transgenic mice expressing CreER.
Estrogen Receptor/ERR  
Breast Cancer  
59
HY-10492 Dinaciclib
Dinaciclib (SCH 727965) is a potent inhibitor of CDK, with IC50s of 1 nM, 1 nM, 3 nM, and 4 nM for CDK2, CDK5, CDK1, and CDK9, respectively.
CDK   Apoptosis  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation   SARS-CoV-2 Infection  
56
HY-10005 Flavopiridol
Flavopiridol (Alvocidib) is a broad spectrum and competitive inhibitor of CDKs, inhibiting CDK1, CDK2, CDK4 with IC50s of 30, 170, 100 nM, respectively.
CDK   Autophagy   HIV   Apoptosis  
Neurological, Eye or Ear Disease   Breast Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection  
54
HY-15676 Idasanutlin
Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors.
MDM-2/p53   E1/E2/E3 Enzyme   Apoptosis   Pyroptosis   Reactive Oxygen Species (ROS)   Caspase  
Musculoskeletal and Skin Disease   Colorectal Cancer   Melanoma   Neuroblastoma   Osteosarcoma   Non-Small Cell Lung Cancer   Acute Myeloid Leukemia   Non-Hodgkin Lymphoma  
52
HY-50696 Nutlin-3
Nutlin-3 is a commercial available p53-MDM2 inhibitor, with Ki of 90 nM.
MDM-2/p53   E1/E2/E3 Enzyme  
Colorectal Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer  
43
HY-17600 Acalabrutinib
Acalabrutinib (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. Acalabrutinib binds covalently to Cys481 in the ATP-binding pocket of BTK. Acalabrutinib demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). Acalabrutinib can be used for CLL research. Acalabrutinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
Btk  
Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Rheumatoid Arthritis  
35
HY-B0469 Medroxyprogesterone acetate
Medroxyprogesterone acetate is a widely used synthetic steroid by its interaction with progesterone, androgen and glucocorticoid receptors.
Progesterone Receptor   Androgen Receptor   Glucocorticoid Receptor   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease   Metabolic or Endocrine Disease   Pain  
35
HY-10984 Pomalidomide
Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
Ligands for E3 Ligase   Molecular Glues   Apoptosis   IKZF Family  
Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer  
35
HY-101563 GSK3326595
GSK3326595 is a protein arginine methyltransferase 5 (PRMT5) inhibitor. GSK3326595 decreases SARS-CoV-2 infection, inhibits cancer cell proliferation and induces pro-inflammatory macrophage polarization and increases hepatic triglyceride levels without affecting atherosclerosis. GSK3326595 can be used for research of relapsed/refractory mantle cell lymphoma.
Histone Methyltransferase   SARS-CoV   MDM-2/p53   CDK   Apoptosis  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Digestive System Inflammation   SARS-CoV-2 Infection  
33
HY-14658 Thalidomide
Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ∼250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties. Thalidomide can work as molecular glue to potentiate substrate.
Ligands for E3 Ligase   Apoptosis   Autophagy   Molecular Glues  
Neurological, Eye or Ear Disease   Prostate Cancer   Pancreatic Cancer   Viral Infection   Digestive System Inflammation   Non-Small Cell Lung Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Lung Fibrosis  
26
HY-N0455 L-Arginine
L-Arginine ((S)-(+)-Arginine) is the substrate for the endothelial nitric oxide synthase (eNOS) to generate NO. L-Arginine is transported into vascular smooth muscle cells by the cationic amino acid transporter family of proteins where it is metabolized to nitric oxide (NO), polyamines, or L-proline. L-Arginine is a potent vasodilator, and can be used to induce experimental acute pancreatitis.
Endogenous Metabolite   NO Synthase   Ligands for E3 Ligase  
Prostate Cancer   Sepsis   Hypertension   Rheumatoid Arthritis  
25
HY-101474A Zanubrutinib
Zanubrutinib (BGB-3111) is a selective and orally active Bruton tyrosine kinase (Btk) inhibitor (IC50: 0.3 nM).
Btk  
Leukemia/Lymphoma/Myeloma   SARS-CoV-2 Infection   Rheumatoid Arthritis  
24
HY-N0171A Beta-Sitosterol (purity>98%)
Beta-Sitosterol (purity>98%) is orally active. Beta-Sitosterol exhibits multiple activities, including anti-inflammatory, anticancer, antioxidant, antimicrobial, antidiabetic, antioxidant enzyme, and analgesic. Beta-Sitosterol inhibits inflammation and impaired adipogenesis in bovine mammary epithelial cells by reducing levels of ROS, TNF-α, IL-1β, and NF-κB p65 and restoring the activity of the HIF-1α/mTOR signaling pathway. Beta-Sitosterol induces apoptosis in cancer cells through ROS-mediated mitochondrial dysregulation and p53 activation. Beta-Sitosterol exerts its anticancer effects in cancer cells by activating caspase-3, caspase-8, and caspase-9, mediating PARP inactivation, MMP loss, altered Bcl-2-Bax ratio, and cytochrome c release. Beta-Sitosterol modulates macrophage polarization and reduces rheumatoid inflammation in mice. Beta-Sitosterol inhibits tumor growth in multiple mouse cancer models. Beta-Sitosterol can be used in the research of arthritis, lung cancer, breast cancer and other cancers, diabetes, etc.
Bacterial   Apoptosis   Reactive Oxygen Species (ROS)   MDM-2/p53   Caspase   PARP   MMP   Bcl-2 Family   HIF/HIF Prolyl-Hydroxylase   TNF Receptor   Interleukin Related   NF-κB   mTOR   Lactate Dehydrogenase   CDK   Glutathione Peroxidase   SOD  
Lung Cancer   Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Bacterial Infection   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
23
HY-14249 Bicalutamide
Bicalutamide is an orally active non-steroidal androgen receptor (AR) antagonist. Bicalutamide can be used for the research of prostate cancer.
Androgen Receptor   Autophagy  
Prostate Cancer   Pancreatic Cancer   Viral Infection   SARS-CoV-2 Infection  
21
HY-W854659 Chlorin e6 trisodium
Chlorin e6 Ce6 (trisodium) is a water-soluble derivative of chlorophyll, belonging to the chlorin class of photosensitizers with an absorption wavelength range of 600-670 nm. Chlorin e6 trisodium emits characteristic red fluorescence upon light excitation, enabling real-time identification of tumor boundaries and progression. Chlorin e6 trisodium can be used for the study of photodynamic therapy (PDT) of cancers (bladder cancer) and fluorescence diagnosis of neoplastic lesions.
Photosensitizer  
Cancer  
20
HY-N0140 Ursolic acid
Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.
Autophagy   Endogenous Metabolite  
Prostate Cancer   Leukemia/Lymphoma/Myeloma  
20
HY-101488 CC-885
CC-885 is a cereblon (CRBN) modulator with potent anti-tumour activity. CC-885 is also a known degrader of GSPT1, inhibiting protein translation.
Molecular Glues   Ligands for E3 Ligase  
Cancer  
20
HY-N0170 Indole-3-carbinol
Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1).
NF-κB   Aryl Hydrocarbon Receptor   E1/E2/E3 Enzyme   Endogenous Metabolite  
Breast Cancer   Prostate Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Chronic Myelogenous Leukemia   SARS-CoV-2 Infection   Obesity  
18
HY-N0486 L-Leucine
L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.
mTOR   Endogenous Metabolite   Ligands for E3 Ligase  
Pancreatic Cancer   Depression   Pain   Glucose Metabolism  
16
HY-16060 Apalutamide
Apalutamide (ARN-509) is a potent and competitive androgen receptor (AR) antagonist, binding AR with an IC50 of 16 nM.
Androgen Receptor  
Castration-Resistant Prostate Cancer   Metastatic Prostate Cancer  
15
HY-Y0966 Glycine
Glycine is an inhibitory neurotransmitter in the CNS and also acts as a co-agonist along with glutamate, facilitating an excitatory potential at the glutaminergic N-methyl-D-aspartic acid (NMDA) receptors. Glycine is orally active. Glycine inhibits the membrane aggregation of NINJ1 and prevents plasma membrane rupture during cell death. Glycine can be used to study cell protection, cancer, neurological diseases, and angiogenesis.
Endogenous Metabolite   Ninjurin   VEGFR   iGluR   PROTAC Linkers   Ligands for E3 Ligase  
Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Ovarian Cancer   Schizophrenia   Pain   Non-Small Cell Lung Cancer   HER-2 Positive Breast Cancer   Multiple Myeloma   HSV Infection   SARS-CoV-2 Infection   Alzheimer's Disease   Lung Fibrosis  
15
HY-19980 Eprenetapopt
Eprenetapopt (APR-246) is a first-in-class, small molecule that restores wild-type p53 functions in TP53-mutant cells. Eprenetapopt triggers apoptosis in tumor cells. Eprenetapopt also targets the selenoprotein thioredoxin reductase 1 (TrxR1), a key regulator of cellular redox balance.
MDM-2/p53   Autophagy   Apoptosis   Ferroptosis  
Colorectal Cancer   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Digestive System Inflammation  
13
HY-101291 Iberdomide
Iberdomide (CC-220) is an orally active and potent cereblon (CRBN) E3 ligase modulator (CELMoD) with an IC50 of ~150 nM for cereblon-binding affinity. Iberdomide, a derivative of Thalidomide (HY-14658), has antitumor and immunostimulatory activities.
Ligands for E3 Ligase   Apoptosis   Molecular Glues  
Digestive System Disease   Leukemia/Lymphoma/Myeloma   Digestive System Inflammation   SARS-CoV-2 Infection  
12
HY-19834 Fenebrutinib
Fenebrutinib (GDC-0853) is a potent, selective, orally available, and noncovalent bruton's tyrosine kinase (Btk) inhibitor with Kis of 0.91 nM, 1.6, 1.3, 12.6, and 3.4 nM for WT Btk, and the C481S, C481R, T474I, T474M mutants. Fenebrutinib has the potential for rheumatoid arthritis and systemic lupus erythematosus research.
Btk  
Leukemia/Lymphoma/Myeloma   Rheumatoid Arthritis  
11
HY-N2371 27-Hydroxycholesterol
27-Hydroxycholesterol (27-OHC) is a selective estrogen receptor modulator and an agonist of the liver X receptor.
Estrogen Receptor/ERR   LXR   Endogenous Metabolite  
Breast Cancer  
10
HY-Y0252 L-Proline
L-Proline is one of the twenty amino acids used in living organisms as the building blocks of proteins.
Endogenous Metabolite   mTOR   Apoptosis   Ligands for E3 Ligase  
Breast Cancer   Pancreatic Cancer   Depression   SARS-CoV-2 Infection  
10
HY-131328 Pirtobrutinib
Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM.
Btk  
Leukemia/Lymphoma/Myeloma   Rheumatoid Arthritis  
9
HY-16985 Darolutamide
Darolutamide (ODM-201) is an orally active competitive androgen receptor (AR) antagonist. Darolutamide has a Ki of 11 nM for rat wild-type AR (wtAR) and IC50 of 26 nM for human wild-type AR (hAR)-mediated transcriptional activation. Darolutamide inhibits testosterone-induced AR nuclear translocation and transcriptional activation. Darolutamide exerts selective effects on AR-positive cells by inhibiting AR-dependent signaling pathways, and its active metabolite retains full antagonistic activity against AR mutants. Darolutamide can be used for the research of prostate cancer, including androgen receptor-dependent prostate cancer.
Androgen Receptor  
Prostate Cancer   Pancreatic Cancer   Non-Small Cell Lung Cancer   Metastatic Breast Cancer  
9
HY-14392 5,6-Dichlorobenzimidazole riboside
5,6-Dichlorobenzimidazole riboside (DRB) is a nucleoside analog that inhibits several carboxyl-terminal domain kinases, including casein kinase II and cell cycle-dependent kinases (CDK). 5, 6-dichlorobenzimidazole riboside has antitumor activity. 5, 6-dichlorobenzimidazole riboside can induce apoptosis.
CDK   Apoptosis  
Digestive System Disease   Breast Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Digestive System Inflammation  
9
HY-N0215 L-Phenylalanine
L-Phenylalanine ((S)-2-Amino-3-phenylpropionic acid) is an essential amino acid isolated from Escherichia coli. L-Phenylalanine is a α2δ subunit of voltage-dependent Ca+ channels antagonist with a Ki of 980 nM. L-phenylalanine is a competitive antagonist for the glycine- and glutamate-binding sites of N-methyl-D-aspartate receptors (NMDARs) (KB of 573 μM ) and non-NMDARs, respectively. L-Phenylalanine is widely used in the production of food flavors and pharmaceuticals.

Source: Escherichia coli

Calcium Channel   iGluR   Endogenous Metabolite   Ligands for E3 Ligase  
Metabolic or Endocrine Disease   Breast Cancer   Depression   Pain   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease   Hypertension  
9
HY-138641 Bavdegalutamide
Bavdegalutamide (ARV-110) is an orally active, specific androgen receptor (AR) PROTAC degrader. Bavdegalutamide promotes ubiquitination and degradation of AR. Bavdegalutamide can be used for the research of prostate cancer (Pink: AR ligand (HY-168299); Blue: E3 ligase ligand (HY-W093272); Black: linker (HY-W091986)).
PROTACs   Androgen Receptor  
8
HY-107608 Leukotriene B4
Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
Endogenous Metabolite   PROTAC Linkers   Leukotriene Receptor  
Cancer   Inflammation or Immune System Disease  
7
HY-109192 Tolebrutinib
Tolebrutinib (SAR442168) is an orally active, selective, and blood-brain barrier-penetrant BTK inhibitor with neuroactive properties. Tolebrutinib is being investigated for use in multiple sclerosis (MS), particularly secondary progressive multiple sclerosis (SPMS)..
Btk  
Experimental Autoimmune Encephalomyelitis   Multiple Sclerosis   Experimental Autoimmune Encephalomyelitis  
7
HY-B0561 Spironolactone
Spironolactone is an aldosterone antagonist that acts on the aldosterone mineralocorticoid receptor (IC50=24 nM) and androgen receptor (IC50=77 nM), promotes podocyte autophagy and regulates pain. Spironolactone improves hypertension-related vascular hypertrophy and remodeling by reducing angiotensin II (Ang II)-induced inflammation, reduces aldosterone-induced vascular and soft tissue calcification through PIT1-dependent signaling, and alleviates vascular dysfunction in type II diabetic mice by reducing oxidative stress and restoring NO/GC signaling; at low concentrations, it and its metabolites can interfere with aldosterone biosynthesis in the adrenal cortex and inhibit voltage-dependent Ca2+ channels to exert antihypertensive effects.
Mineralocorticoid Receptor   Androgen Receptor   Autophagy   Calcium Channel  
Prostate Cancer   Viral Infection   Glucose Metabolism   Parkinson's Disease   Hypertension  
7
HY-100354 C16-Ceramide (d18:1/16:0)
C16-Ceramide (d18:1/16:0) is a natural small molecule activating p53 through the direct and selective binding.
MDM-2/p53   Apoptosis   Endogenous Metabolite  
Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Digestive System Inflammation  
7
HY-128757 Remibrutinib
Remibrutinib, is a potent and orally active bruton tyrosine kinase (BTK) inhibitor with an IC50 value of 1 nM. Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib has the potential for Chronic urticaria (CU) treatment.
Btk  
Leukemia/Lymphoma/Myeloma   Rheumatoid Arthritis  
6
HY-138642 Vepdegestrant
Vepdegestrant (ARV-471) is an orally active PROTAC estrogen receptor degrader against breast cancer. Vepdegestrant is a hetero-bifunctional molecule that facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex. Vepdegestrant leads to the ubiquitylation and subsequent degradation of estrogen receptors via the proteasome. Vepdegestrant robustly degrades ER in ER-positive breast cancer cell lines with a half-maximal degradation concentration (DC50) of about 2 nM.
PROTACs   Estrogen Receptor/ERR  
Luminal Breast Cancer  
6
HY-12316 20(S)-Hydroxycholesterol
20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator that selectively targets the Smoothened (Smo) of the Hedgehog pathway with an EC50 of ~30 μM (Hedgehog). 20(S)-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo in a stereoselective manner, activating downstream Gli transcription factors (without inducing transcription of receptor genes in the Wnt pathway). 20(S)-Hydroxycholesterol enhances osteogenic differentiation of bone marrow stromal cells and synergistically activates the Raf/MEK/ERK pathway with Simvastatin (HY-17502) to promote bone regeneration. 20(S)-Hydroxycholesterol can be used to study the mechanisms of developmental biology, oncology, bone, and angiogenesis.
Smo   Endogenous Metabolite  
Cancer   Osteogenic Differentiation  
5
HY-N0242 Fraxinellone
Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1.
PD-1/PD-L1   HIF/HIF Prolyl-Hydroxylase   STAT  
Inflammation or Immune System Disease   Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Obesity  
4
HY-N6769 Radicicol
Radicicol is an inhibitor of Hsp90 with an IC50 value < 1 μM, and leads to proteasomal degradation. Radicicol exhibits inhibition on PDK with IC50s of 230 μM (PDK1) and 400 μM (PDK3). Radicicol is an antifungal and antimalarial antibiotic, impairs mitochondrial replication by targeting P. falciparum topoisomerase VIB. Radicicol is also an inhibitor of fat mass and obesity-associated protein (FTO), with an IC50 value of 16.04 μM.

Source: Penicillium meleagrinum

HSP   Bacterial   Antibiotic   Parasite  
Infection  
4
HY-N1423 Glycocholic acid
Glycocholic acid is a bile acid derivative. Glycocholic acid downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Glycocholic acid inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Glycocholic acid modulates related bile acid receptor signaling. Glycocholic acid suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Glycocholic acid can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).
G protein-coupled Bile Acid Receptor 1   FXR   LPL Receptor   Bcl-2 Family   Apoptosis   MDM-2/p53   P-glycoprotein   Bacterial   Caspase   Endogenous Metabolite  
Metabolic or Endocrine Disease   Lung Cancer   Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis  
4
HY-153321 Bexobrutideg
Bexobrutideg (NX-5948) is an orally active chimeric targeting molecule (CTM) that induces specific BTK protein degradation by the cereblon E3 ligase (CRBN) complex without degradation of other cereblon neo-substrates. Bexobrutideg mediates potent anti-inflammatory activity via BTK degradation with resultant inhibition of B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models that contain either wild-type BTK or BTKi-resistant mutations. Bexobrutideg is efficacious in a mouse collageninduced arthritis (CIA) model. Bexobrutideg can cross the blood brain barrier (BBB). Bexobrutideg is a PROTAC composed of the ligand for target protein, a linker, and a cereblon E3 ligase (CRBN) complex (Red: BTK ligand (HY-170324); Blue: CRBN ligand (HY-171893); Black: linker).
PROTACs   Btk  
Inflammation or Immune System Disease  
3
HY-16950A (E/Z)-4-Hydroxytamoxifen
(E/Z)-4-Hydroxytamoxifen (Afimoxifene) is a racemic compound of (Z)-4-Hydroxytamoxifen and (E)-4-Hydroxytamoxifen isomers. (E/Z)-4-Hydroxytamoxifen is a selective estrogen receptor modulator with mixed estrogenic and antiestrogenic activity, which is also an active metabolite of Tamoxifen (HY-13757A). (E/Z)-4-Hydroxytamoxifen is an agonist of the G protein-coupled estrogen receptor (GPER) with relatively low affinity (100-1000 nM). (E/Z)-4-Hydroxytamoxifen is promising for research of cyclical mastalgia, such as breast pain, tenderness, and nodularity.
Estrogen Receptor/ERR   Adhesion G Protein-coupled Receptors (AGPCRs)   Drug Metabolite  
Cancer   Metabolic or Endocrine Disease  
3
HY-112166 Rilzabrutinib
Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM.
Btk  
Metabolic or Endocrine Disease   Leukemia/Lymphoma/Myeloma   Rheumatoid Arthritis  
2
HY-153342 Luxdegalutamide
Luxdegalutamide (ARV-766) is an orally active protein hydrolysis targeted chimeric (PROTAC) targeting androgen receptor (AR), which can degrade AR resistance related mutants, including T878/H875/L702 mutants. Luxdegalutamide has anti-tumor activity and can be used in the study of castration resistant prostate cancer.
PROTACs   Androgen Receptor  
Cancer  
2
HY-P99575 Tarlatamab
Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research.

Species: Human

Notch  
Inflammation or Immune System Disease   Respiratory Disease   Small Cell Lung Cancer  
2
HY-10219G Rapamycin (GMP)
Rapamycin (Sirolimus) (GMP) is Rapamycin (HY-10219) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin is a molecular glue that binds FKBP12 and mTOR proteins together, thereby inhibiting mTOR kinase activity. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant.
mTOR   FKBP   Molecular Glues   Fungal   Autophagy   Endogenous Metabolite   Antibiotic   Bacterial  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Fungal Infection   Pain   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
1
HY-N1453 Hypocrellin B
Hypocrellin B, a pigment isolated from the fungi Hypocrella bambusae and Shiraia bambusicola, is an apoptosis inducer. Hypocrellin B can be used as a photosensitizer for photodynamic therapy of cancer. Hypocrellin B also has antimicrobial and antileishmanial activities.

Source: Hypocrella bambusae, Shiraia bambusicola

Apoptosis   Fungal   Parasite  
Infection  
1
HY-13756S Tacrolimus-13C,d2
Tacrolimus-13C,d2 (FK506-13C,d2) is the 13C, deuterated-labeled Tacrolimus (HY-13756). Tacrolimus (FK506), a molecular glue, a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.
Isotope-Labeled Compounds   Phosphatase   FKBP   Molecular Glues   Bacterial   Autophagy   Antibiotic  
Inflammation or Immune System Disease  
1
HY-B0579S Cyclosporin A-d4
Cyclosporin A-d4 (Cyclosporine A-d4) is the deuterated-labeled Cyclosporin A (HY-B0579). Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM. Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion.
Isotope-Labeled Compounds   Molecular Glues   Complement System   Antibiotic   Cyclophilin  
Neurological, Eye or Ear Disease   Breast Cancer   Prostate Cancer   Viral Infection   Autoimmune Disease   SARS-CoV-2 Infection   Lung Fibrosis  
1
HY-N6929 Angelic acid
Angelic acid is a ferroptosis inducer, targeting NRF2 degradation. Angelic acid binds to NRF2 protein and promotes NRF2 degradation via ubiquitination-proteasome pathway, relieves the inhibitory effect of NRF2 on oxidative stress and lipid peroxidation. Then, Angelic acid induces ferroptosis in tumor cells. Angelic acid can enhance the accumulation of intracellular reactive oxygen species (ROS), upregulate ferroptosis-related markers CHAC1 and PTGS2, and synergize with ferroptosis inducers to enhance anti-tumor effects. Angelic acid also has the activity of scavenging UVA-induced ROS in vitro, inhibiting skin fibroblast senescence and extracellular matrix degradation. Angelic Acid helps wound healing with sedative activity.
Ferroptosis   Keap1-Nrf2   Reactive Oxygen Species (ROS)  
Cancer   Inflammation or Immune System Disease   Parkinson's Disease  
1
HY-113011 Maltotriose
Maltotriose is a maltooligosaccharide and a specific inducer of the Escherichia coli maltose operon. The oligosaccharide structure of Maltotriose acts as a highly efficient drug delivery carrier, which significantly enhances the targeting ability and water solubility of photosensitizers in photodynamic therapy for pancreatic cancer.
Endogenous Metabolite  
1
HY-153220 Zelebrudomide
Zelebrudomide is an orally active BTK-targeting PROTAC degrader, with DC50 values of 4.5 nM and 31 nM against wild-type BTK and BTKC481S mutant, respectively. Zelebrudomide recruits the cereblon E3 ubiquitin ligase complex to mediate the degradation of BTK. Zelebrudomide also acts as a molecular glue to bind the cereblon E3 ubiquitin ligase complex, mediating the degradation of IKZF1 and IKZF3. Zelebrudomide can be used in the research of B-cell malignancies.
PROTACs   Btk  
Cancer  
1
HY-158101 BMS-986365
BMS-986365 (CC-94676) is an orally active and selective targeted androgen receptor (AR) PROTAC degrader (DC50 of 10-40 nM). BMS-986365 is capable of inducing cereblon (CRBN) E3 ligase-dependent ubiquitination and degradation of the androgen receptor (AR), as well as various AR mutants. BMS-986365 shows no degradation of the close AR family members estrogen receptor (ER), progesterone receptor (PR), and glucocorticoid receptor (GR). BMS-986365 shows significant in vivo potency, degrading AR, inhibiting AR signaling, and restricting tumor growth in animal models of advanced prostate cancer. BMS-986365 can be used for the study of metastatic castration-resistant prostate cancer (mCRPC).
PROTACs   Androgen Receptor  
Prostate Cancer  
1
HY-13756S2 Tacrolimus-d3
Tacrolimus-d3 (FK506-d3) is the deuterated-labeled Tacrolimus (HY-13756). Tacrolimus (FK506), a molecular glue, a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.
Isotope-Labeled Compounds   Phosphatase   FKBP   Molecular Glues   Bacterial   Autophagy   Antibiotic  
Inflammation or Immune System Disease  
/
HY-D3392 Thalidomide-cyanine 5
Thalidomide-cyanine 5 is a fluorescent probe prepared by conjugating the CRBN binder Thalidomide (HY-14658) with the near-infrared fluorescent dye Cy5. Thalidomide-cyanine 5 binds to DDB1-CRBN protein complex with a Kd of 121.6 nM. Thalidomide-cyanine 5 binds to CRBN to form a binary complex, and is mainly used for the visual tracking research of degradants such as PROTAC (Ex/Em = 650/665 nm).
Fluorescent Dye   Ligands for E3 Ligase  
/
HY-P991234 COVA208
COVA208 is a bispecific FynomAb (a fusion protein of an antibody and a Fyn SH3-derived binding protein) that targets HER2. COVA208 induces the degradation of HER2, reduces the levels of HER2, HER3, and EGFR, thereby effectively blocking the downstream signaling pathways of HER2, including the HER3-PI3K-AKT and MAPK pathways, and simultaneously inducing apoptosis of tumor cells. COVA208 is promising for research of cancers, such as HER2-positive breast cancer, gastric cancer, and colorectal cancer.

Species: Human

EGFR   p38 MAPK   PI3K   Akt  
Cancer  
/
HY-137474 Purpurin 18 methyl ester
Purpurin 18 methyl ester, a chlorophyll-a derivative, is a photosensitizer that can be used in photodynamic therapy (PDT). Purpurin 18 methyl ester has photodynamic activity to induce cancer cell death.

Source: sponge Stelletta clavosa

Photosensitizer  
/
HY-181000 PROTAC PLK1 Degrader-3
PROTAC PLK1 Degrader-3 (Compound DD-1) is a PLK1 PROTAC degrader based on the N-deglycosylation pathway, with a Kd value of 2.2 μM. The cell penetration ability of PROTAC PLK1 Degrader-3 is limited and a higher concentration is required to achieve significant degradation effects. PROTAC PLK1 Degrader-3 can be used for research on non-small cell lung cancer.
PROTACs   Polo-like Kinase (PLK)  
Non-Small Cell Lung Cancer  
/
HY-141520G ART558 (GMP)
ART558 (GMP) is ART558 (HY-141520) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. ART558 is a potent, selective and allosteric DNA polymerase theta (Polθ) inhibitor (IC50=7.9 nM). ART558 elicits BRCA-gene synthetic lethality and DNA damage. ART558 can be used for the research of cancer, such as breast cancer.
DNA/RNA Synthesis  
Cancer  
/
HY-40171S NH2-C2-NH-Boc-d4
NH2-C2-NH-Boc-d4 is the deuterium labeled NH2-C2-NH-Boc. NH2-C2-NH-Boc (PROTAC Linker 22) is a alkyl chain-based PROTAC linker can be used in the synthesis of PROTACs.
PROTAC Linkers  
Cancer  
/
HY-N10332 Leptosphaerodione
Leptosphaerodione, isolated from Remotididymella sp. Fungus, is a potent ubiquitin-proteasome system (UPS) inhibitor. Leptosphaerodione exhibits cytotoxicity in HeLa cells with IC50 value of 3.2 μM. Anti-tumor agent.

Source: Remotididymella sp.

Proteasome  
Cancer  
/
HY-W009450S 1,7-Dibromoheptane-d14
1,7-Dibromoheptane-d14 (Heptamethylene dibromide-d14) is the deuterium labeled 1,7-Dibromoheptane (HY-W009450). 1,7-Dibromoheptane is a PROTAC linker that can be used in the synthesis of PROTACs.
Isotope-Labeled Compounds   PROTAC Linkers  
/
HY-W005059S 2-(4-Aminophenyl)ethanol-d6
2-(4-Aminophenyl)ethanol-d6 (p-aminophenylethanol-d6) is the deuterium labeled 2-(4-Aminophenyl)ethanol (HY-W005059). 2-(4-Aminophenyl)ethanol is a PROTAC linker that can be used in the synthesis of PROTACs.
Isotope-Labeled Compounds   PROTAC Linkers  
/
HY-P992450 REGN6569
REGN6569 is a fully human IgG1 monoclonal antibody targeting glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) with high specificity for GITR. REGN6569 exerts stronger in vitro antibody-dependent cell-mediated cytotoxicity (ADCC) against regulatory T cells expressing GITR. REGN6569 selectively depletes regulatory T cells via antibody-dependent cell-mediated cytotoxicity and increases the proportion of proliferative natural killer (NK) cells in peripheral blood. REGN6569 is applicable for advanced solid malignancies. Isotype control: HY-P99001.

Species: Human

TNF Receptor  
Cancer  
/
HY-A0003S2 Lenalidomide-13C5,15N
Lenalidomide-13C5,15N is 15N and 13C labeled Lenalidomide (HY-A0003). Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
Ligands for E3 Ligase   Molecular Glues   Apoptosis   Isotope-Labeled Compounds  
Cancer   Inflammation or Immune System Disease  
/
HY-15947G Ravoxertinib (GMP)
Ravoxertinib GMP is Ravoxertinib (HY-15947) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma.
ERK   c-Myc   Hexokinase   Lactate Dehydrogenase  
Breast Cancer   Ovarian Cancer   Squamous Cell Carcinoma  
/
HY-W007559S 6-Bromohexanoic acid-d6
6-Bromohexanoic acid-d6 (6-bromohexanoate-d6) is the deuterium labeled 6-Bromohexanoic acid (HY-W007559). 6-Bromohexanoic acid (6-bromohexanoate) is a PROTAC linker that can be used in the synthesis of PROTACs.
Isotope-Labeled Compounds   PROTAC Linkers  
/
HY-P11631 Arg12
Arg12, a 12-amino acid peptide sequence, is an E3 ubiquitin ligase ligand. Arg12 can be used to synthesize PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989). Arg12 can also act as a cell transmembrane peptide (CPP), facilitating the entire molecule to enter the cell.
Ligands for E3 Ligase  
Cancer  
/
HY-133376 DBCO-NHCO-PEG12-biotin
DBCO-NHCO-PEG12-biotin is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. DBCO-NHCO-PEG12-biotin is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
PROTAC Linkers  
Cancer  
/
HY-P11792 CP2-CPP
CP2-CPP is a conjugate of p27 Analogue CP2 (HY-P11020) and Antennapedia Peptide (HY-P0307). CP2-CPP crosses cell membranes and localizes to live cell cytosol. CP2-CPP blocks SCFSkp2/Cks1-p27 interaction to inhibit p27 ubiquitination and degradation, restoring p27 levels and inhibiting cell proliferation. CP2-CPP can be used for the research of cancer, such as breast cancer.
E1/E2/E3 Enzyme  
Breast Cancer  
/
HY-P5327 r8 Bid BH3
r8 Bid BH3 is a biological active peptide. (The Bid BH3 is a pro-apoptotic member of the 'BH3-only' subset of BCL-2 family proteins that constitute a critical control point in apoptosis. r8BIDBH3 is lethal to human leukemia cell lines that expresse Bcl-2. The Bcl-2 antagonists may have the potential to be efficacious in cancer therapy. Poly-D-arginine (d-isomer as denoted by rrrrrrrr) is fused to the Bid BH3 peptide to facilitate cellular uptake of the peptide.)
Bcl-2 Family  
Cancer  
/
HY-130768 N-(Azido-PEG3)-N-Fluorescein-PEG3-acid
N-(Azido-PEG3)-N-Fluorescein-PEG3-acid is a PEG-based PROTAC linker which contains azide, fluorescein and carboxylic acid moieties. N-(Azido-PEG3)-N-Fluorescein-PEG3-acid is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
PROTAC Linkers  
Cancer  
/
HY-W707693 Scyllo-Inositol-d6
Scyllo-Inositol-d6 is the deuterium labeled Scyllo-Inositol (HY-W010041). Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease.
Isotope-Labeled Compounds   α-synuclein   Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-W127725 Thymolphthalexon tetrasodium
Thymolphthalexon (tetrasodium) is an organic compound commonly used as a reagent in biochemical assays. It belongs to the family of thioxanthone derivatives and has strong antioxidant properties. Thymolphthalexon has several applications in the study of free radical response, oxidative stress, and aging. In addition, it can be used as a photosensitizer in photodynamic therapy for the improvement of cancer and other diseases.
Biochemical Assay Reagents  
/
HY-15150G Bemcentinib (GMP)
Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer.
TAM Receptor  
/
HY-P10981 ErbB2 peptide
ErbB2 peptide is a peptide ligand of E3 ubiquitin ligase targeting PI3K for peptide PROTACs.
PI3K   Ligands for E3 Ligase  
Cancer  
/
HY-D2095 Medical fluorophore 33
Medical fluorophore 33 is a novel quinoline-isoquinoline salt. Medical fluorophore 33 exhibits a strong fluorescent signal, good microsomal stability and high biocompatibility in vivo. Medical fluorophore 33 has antitumor activity in colorectal cancer mice.
Fluorescent Dye  
/
HY-155887 DSPE-PEG-Amine, MW 3400 ammonium
DSPE-PEG-Amine (DSPE-PEG-NH2), MW 3400 ammonium is an amino-functionalized PEGylated phospholipid. It serves not only as a key component for preparing σ receptor-targeted liposomes (such as anisamide-modified lipids) but also as a starting material for synthesizing click chemistry- and tumor-targeted lipids including DSPE-PEG-DBCO (HY-155788) and DSPE-PEG2000-TCO (HY-170704). DSPE-PEG-Amine, MW 3400 ammonium effectively modulates the ζ potential of nanoparticles, enables complexation with nucleic acids or proteins to protect DNA from nuclease degradation, and supports ligand conjugation on the nanoparticle surface. It is used in studies related to DU-145 tumors, breast cancer, and other relevant research.
Liposome  
Breast Cancer  
/
HY-P10711 ALA-A2 peptide
ALA-A2 is an anticancer peptide discovered in alpha-lactalbumin that selectively kills cancer cells by inducing Autophagy. ALA-A2 has cell-penetrating capabilities, allowing it to effectively enter cells without relying on membranolytic effects. In A549 lung cancer cells, ALA-A2 demonstrates significant dose-dependent anticancer activity. ALA-A2 holds promise for research in cancer therapy and autophagy regulation.
Autophagy  
/
HY-N2991R Dehydropachymic acid (Standard)
Dehydropachymic acid (Standard) is the analytical standard of Dehydropachymic acid. This product is intended for research and analytical applications. Dehydropachymic acid is one of the major triterpenes isolated from Poria cocos. Dehydropachymic acid is more effective in autophagy-lysosome pathway (ALP) impaired cells rather than normal cells.
Reference Standards   Autophagy  
Neurological, Eye or Ear Disease  
/
HY-D2317 HaloFlipper 30
HaloFlipper 30 is a fluorescent probe that covalently reacts with HaloTag fusion proteins to form an ester bond, which allows the probe to be stably attached to membrane structures. HaloFlipper 30 has high specificity, precision and good cell permeability.
Fluorescent Dye  
/
HY-180991 Arg12-AHX
Arg12-AHX is a synthetic E3 ligase-ligand conjugate that can be used for the synthesis of PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989). PROTAC PLK1 Degrader-2 is a PLK1 PROTAC degrader with anti-tumor activity.
E3 Ligase Ligand-Linker Conjugates  
Cancer  
/
HY-P992382 IC 100
IC 100 is a humanized IgG4κ monoclonal antibody targeting apoptosis-associated speck-like protein (ASC) with blood-brain barrier permeability. IC 100 specifically inhibits ASC after being endocytosed via its Fc segment, blocks ASC polymerization and inflammasome activation, suppresses IL-1β release, forms complexes with ASC and TRIM21, and evades TRIM21-mediated proteasomal degradation. IC 100 alleviates symptoms associated with autoimmune encephalomyelitis, reduces immune cell infiltration and microglial activation in the mouse EAE model. IC 100 is suitable for research on neuroinflammatory and inflammasome-related diseases such as multiple sclerosis. Isotype comparison: HY-P99003.

Species: Human

Interleukin Related  
Multiple Sclerosis  
/
HY-P992353 ES009
ES009 is a high-affinity LILRB2 antagonist, with IC50 values of 14.07 nM and 18.61 nM for inhibiting hLILRB2-huANGPTL3 and hLILRB2-huANGPTL4, respectively. ES009 specifically blocks the interactions between LILRB2 and MHC class I as well as non-MHC ligands, thereby effectively inhibiting receptor activation. ES009 can reprogram anti-inflammatory myeloid cells and induce their conversion to a pro-inflammatory phenotype, and also reverse the T cell suppression mediated by macrophages. When combined with anti-PD-1 blockade therapy, ES009 synergistically enhances T cell activation. ES009 can be used in research related to advanced solid tumors and ovarian cancer.

Species: Human

LILRB  
Ovarian Cancer  
/
HY-171459S LEQ803-d3
LEQ803-d3 (N-Desmethyl Ribociclib-d3) is the deuterium labeled LEQ803 (HY-171459). LEQ803 (N-Desmethyl Ribociclib) is a drug metabolite of the CDK4/6 inhibitor Ribociclib (HY-15777), which is produced through metabolism by CYP3A4. LEQ803 has potential application value in the field of oncology.
Isotope-Labeled Compounds   Drug Metabolite   Cytochrome P450  
Cancer  
/
HY-N0242R Fraxinellone (Standard)
Fraxinellone (Standard) is the analytical standard of Fraxinellone. This product is intended for research and analytical applications. Fraxinellone is isolated from the root bark of the Rutaceae plant, Dictamnus dasycarpus. Fraxinellone is a PD-L1 inhibitor and inhibits HIF-1α protein synthesis without affecting HIF-1α protein degradation. Fraxinellone has the potential to be a valuable candidate for cancer treatment by targeting PD-L1.
Reference Standards   PD-1/PD-L1   HIF/HIF Prolyl-Hydroxylase   STAT  
Inflammation or Immune System Disease  
/
HY-N0690R Schisandrin C (Standard)
Schisandrin C (Standard) (Schizandrin-C (Standard)) is the analytical standard of Schisandrin C (HY-N0690). This product is intended for research and analytical applications. Schisandrin C (Schizandrin-C) is a phytochemical lignan isolated from Schizandra chinensis. Schisandrin C has diverse biological activities, including anticancer, anti-inflammatory and antioxidant effects. Schisandrin C is a molecular glue. Schisandrin C can be used for cancer, alzheimer’s disease, and liver diseases research. Schisandrin C induces cell apoptosis.
Reference Standards   Apoptosis  
Cancer   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-180990 POI ligand-3
POI ligand-3 (Compound 4j) is a type of peptide-based PLK1 PBD inhibitor. POI ligand-3 can act as a target protein ligand and be used for the synthesis of PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989).
Ligands for Target Protein for PROTAC   Polo-like Kinase (PLK)  
Cancer  
/
HY-170126S 9-Amino-1,2,3,4-tetrahydroacridin-1-ol-d3 Maleate
9-Amino-1,2,3,4-tetrahydroacridin-1-ol-d3 Maleate is the deuterium labeled CRBN ligand-74 (HY-170126). CRBN ligand-74 is a CRBN-type E3 ubiquitin ligase ligand that can be used to prepare PROTAC.
Isotope-Labeled Compounds   Ligands for E3 Ligase  
Cancer  
/
HY-W766548 Floxuridine-13C,15N2
Floxuridine-13C,15N2 (5-Fluorouracil 2'-deoxyriboside-13C,15N2) is the 13C- and 15N-labeled labeled Floxuridine (HY-B0097). Floxuridine (5-Fluorouracil 2'-deoxyriboside) is a pyrimidine analog and known as an oncology antimetabolite. Floxuridine inhibits Poly(ADP-Ribose) polymerase and induces DNA damage by activating the ATM and ATR checkpoint signaling pathways in vitro. Floxuridine is a extreamly potent inhibitor for S. aureus infection and induces cell apoptosis. Floxuridine has antiviral effects against HSV and CMV.
Isotope-Labeled Compounds   CMV   DNA/RNA Synthesis   Nucleoside Antimetabolite/Analog   Bacterial   Apoptosis   HSV  
Cancer  
/
HY-174925 Thalidomide-O-PEG3-COOH
Thalidomide-O-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
E3 Ligase Ligand-Linker Conjugates  
Cancer  
/
HY-N6929R Angelic acid (Standard)
Angelic acid (Standard)) is the analytical standard of Angelic acid (HY-N6929). This product is intended for research and analytical applications. Angelic acid is a ferroptosis inducer, targeting NRF2 degradation. Angelic acid binds to NRF2 protein and promotes NRF2 degradation via ubiquitination-proteasome pathway, relieves the inhibitory effect of NRF2 on oxidative stress and lipid peroxidation. Then, Angelic acid induces ferroptosis in tumor cells. Angelic acid can enhance the accumulation of intracellular reactive oxygen species (ROS), upregulate ferroptosis-related markers CHAC1 and PTGS2, and synergize with ferroptosis inducers to enhance anti-tumor effects. Angelic acid also has the activity of scavenging UVA-induced ROS in vitro, inhibiting skin fibroblast senescence and extracellular matrix degradation. Angelic Acid helps wound healing with sedative activity.
Reference Standards   Ferroptosis   Keap1-Nrf2   Reactive Oxygen Species (ROS)  
Cancer   Neurological, Eye or Ear Disease  
/
HY-W141926 N-Glutarylglycine
N-Glutarylglycine is a PROTAC linker that can be used to synthesize PROTACs, such as PROTAC MPS1 degrader 1 (HY-168540).
PROTAC Linkers  
/
HY-W035399S1 D-Lysine-d4 dihydrochloride
D-Lysine-d4 dihydrochloride is the d4-labeled D-Lysine (HY-Y1091). D-Lysine is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine blocks renal uptake of 111In/90Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine can be used in research related to cancer and diabetes.
Isotope-Labeled Compounds   Drug Isomer  
Cancer   Glucose Metabolism  
/
HY-P3627 Nagrestipen
Nagrestipen, a human macrophage inflammatory protein-1 alpha (MIP-1α) variant, also known as ECI 301. Nagrestipen has antitumor activity and can be used in therapeutic trials to study cancer, tumors, metastases, radiation oncology, and tumor metastasis.
Drug Derivative  
/
HY-P5415 DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS
DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS is a biological active peptide. (DABCYL-GABA-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-EDANS is also called HIV protease substrate I in some literature. It is widely used for the continuous assay for HIV protease activity. The 11-Kd protease (PR) encoded by the human immunodeficiency virus 1 (HIV-1) is essential for the correct processing of viral polyproteins and the maturation of infectious virus, and is therefore a target for the design of selective acquired immunodeficiency syndrome (AIDS) therapeutics. The FRET-based fluorogenic substrate is derived from a natural processing site for HIV-1 PR. Incubation of recombinant HIV-1 PR with the fluorogenic substrate resulted in specific cleavage at the Tyr-Pro bond and a time-dependent increase in fluorescence intensity that is linearly related to the extent of substrate hydrolysis. The fluorescence quantum yields of the HIV-1 PR substrate in the FRET assay increased by 40.0- and 34.4-fold, respectively, per mole of substrate cleaved. Because of its simplicity and precision in the determination of reaction rates required for kinetic analysis, this substrate offers many advantages over the commonly used HPLC or electrophoresis-based assays for peptide substrate hydrolysis by retroviral PRs. Abs/Em = 340nm/490nm.)
HIV  
/
HY-P11129 MAGE-A4 (286-294)
MAGE-A4 (286-294) is a polypeptide derived from the 286th to 294th amino acids of the MAGE-A4 protein. MAGE-A4 (286-294) binds HLA-­A*02 with an affinity of 560.08 nM and an IC50 of 8.52 nM. MAGE-A4 (286-294) can be detected in various types of cancers (such as esophageal cancer, lung squamous cell carcinoma, bladder cancer). MAGE-A4 (286-294) can be used to produce CAR-T cells and to develop CAR-T cell therapy.
Others  
Cancer  
/
HY-W017440S Triethylene glycol-d12
Triethylene glycol-d12 (PROTAC Linker 25-d12) is the deuterium labeled Triethylene glycol (HY-W017440). Triethylene glycol (PROTAC Linker 25) is a PEG-based PROTAC linker can be used in the synthesis of PROTACs.
Isotope-Labeled Compounds   PROTAC Linkers  
/
HY-W743931 2-Azidoethanol-d4
2-Azidoethanol-d4 is the deuterium labeled Azido-PEG1 (HY-138461). Azido-PEG1 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. Azido-PEG1 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
Isotope-Labeled Compounds   PROTAC Linkers  
Cancer  
/
HY-126468 Abieslactone
Abieslactone is a compound with anti-tumor promoting activity, exhibiting significant potential for therapeutic applications in oncology.
Endogenous Metabolite  
Cancer  
/
HY-N16394 4-Hydroxyscytalone
4-Hydroxyscytalone (Compound 3) is a microbial secondary metabolite. 4-Hydroxyscytalone can be isolated from the oak fungus Diplodia corticola. 4-Hydroxyscytalone has toxicity against Artemia salina with a LC50 of 90.6 μ/mL, but no significant antifungal activity. 4-Hydroxyscytalone can be used for cancer therapy research.

Source: Xylaria polymorpha

Endogenous Metabolite  
Cancer  
/
HY-P11493 ALAPYIP
ALAPYIP is a ligand for E3 ligase. ALAPYIP recruits the VHL-E3 ubiquitin ligase. ALAPYIP can be used for the synthesis of FPP29 (HY-P11228).
Ligands for E3 Ligase  
/
HY-P11640 Vpr (1-14)
Vpr (1-14) is a viral protein R and acts as an accessory protein of HIV-1. Vpr (1-14) can binds to Cul4A-DDB1-DCAF1 E3 ligase complex and can be used as an E3 ligase-binding component in PROTACs. Vpr (1-14) can be used to synthesize PROTAC BRD4 Degrader-43 (HY-181164).
Ligands for E3 Ligase   HIV  
HIV Infection  
/
HY-P991744 Anti-Mouse CXCR4 Antibody (Cx4Mab-1)
Anti-Mouse CXCR4 Antibody is a monoclonal antibody that specifically recognizes murine CXCR4 (C-X-C chemokine receptor 4), also known as fusin or CD184. CXCR4 is a seven-transmembrane G protein–coupled receptor whose principal endogenous ligand is CXCL12 (stromal cell–derived factor-1α, SDF-1α) and is widely expressed in hematopoietic cells, endothelial cells, neurons, as well as embryonic and adult stem cells. The CXCR4–CXCL12 signaling axis activates multiple downstream pathways, including ERK1/2, Ras, p38 MAPK, PLC/MAPK, and SAPK/JNK, thereby regulating cell survival, proliferation, migration, and stemness maintenance. Aberrant overexpression of CXCR4 is closely associated with poor prognosis and metastasis in various cancers, with CXCR4-positive tumor cells preferentially home to CXCL12-rich tissues such as the liver, bone marrow, lung, and lymph nodes. Accordingly, CXCR4 and its CXCL12-related antagonists emerge as attractive targets for experimental anticancer therapy. Anti-Mouse CXCR4 Antibody is generated using a cell-based immunization and screening strategy and exhibits high affinity for both endogenous and exogenous murine CXCR4. Anti-Mouse CXCR4 Antibody can be used for thestudy of chronic lymphocytic leukemia and multiple myeloma.
CXCR  
Chronic Lymphocytic Leukemia   Multiple Myeloma  
/
HY-W024365R 3-tert-Butyl-4-methoxyphenol (Standard)
3-tert-Butyl-4-methoxyphenol (Standard) is the analytical standard of 3-tert-Butyl-4-methoxyphenol. This product is intended for research and analytical applications. 3-tert-Butyl-4-methoxyphenol is a PROTAC linker, belongs to alkyl/ether class, with insecticidal activity. 3-tert-Butyl-4-methoxyphenol also induced increased activities of glutathione (GSH) S-transferase and epoxide hydrolase in the liver and forestomach tissues of A/HeJ mice, regulating the carcinogen metabolism system.
PROTAC Linkers   Reference Standards  
Cancer  
/
HY-40178S NH2-C4-NH-Boc-d8
NH2-C4-NH-Boc-d8 is the deuterium labeled NH2-C4-NH-Boc (HY-40178). NH2-C4-NH-Boc (compound 15) is a PROTAC linker, which refers to the Alkyl/ether composition. NH2-C4-NH-Boc can be used in the synthesis of a series of PROTACs. PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.
Isotope-Labeled Compounds   PROTAC Linkers  
/
HY-D2912 Cys-shift probe-1
Cys-shift probe-1 (compound 13) is a potent Cys-shift probe. Cys-shift probe-1 can improve the ion mobility of labeled peptides and be used in protein analysis.
Biochemical Assay Reagents  
/
HY-P992339 cT84.66
cT84.66 is a highly efficient tumor-targeting agent against carcinoembryonic antigen (CEA). cT84.66 engages in bivalent binding with CEA via variable region antigen-binding sites, enabling precise targeting of CEA-producing tumor cells for delivery of therapeutic radiation. cT84.66 exhibits high tumor uptake rate, rapid clearance rate, and excellent tumor-to-blood ratio. With dual functions as an imaging agent and an antibody-directed radiotherapy agent, cT84.66 is widely used in studies of colorectal cancer and metastatic CEA-positive malignancies.

Species: Human

Radionuclide-Drug Conjugates (RDCs)  
Colorectal Cancer  
/
HY-14397G Indomethacin (GMP)
Indomethacin (GMP) is Indomethacin (HY-14397) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Indomethacin (Indometacin) is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin has anticancer activity and anti-infective activity. Indomethacin can be used for cancer, inflammation and viral infection research.
Antibiotic   COX   Bacterial   Influenza Virus  
Inflammation or Immune System Disease  
/
HY-W127809 Chlorin e4
Chlorin e4 is an organic compound belonging to the family of chlorins, which are macrocyclic compounds with a similar structure to porphyrins. It is commonly used to improve photodynamic therapy for cancer and other diseases. Chlorin e4 has multiple applications in medical research, including as a photosensitizer for localized tumor destruction. In addition, its antimicrobial properties and potential use in disinfection applications were investigated.
Biochemical Assay Reagents  
/
HY-P10513 AcrAP1
AcrAP1 (AP1-Z1) is an antimicrobial peptide found in the venom of the Arabian scorpion (Androctonus crassicauda). AcrAP1 has antimicrobial activity and can inhibit the growth of Gram-positive and Gram-negative bacteria as well as yeast. AcrAP1 exerts antitumor activity by promoting apoptosis of cancer cells and inhibiting angiogenesis. AcrAP1 can be used in cancer therapy research.
Bacterial   Fungal   Apoptosis  
Infection  
/
HY-10984S Pomalidomide-d5
Pomalidomide-d5 is deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
Isotope-Labeled Compounds   Ligands for E3 Ligase   Molecular Glues   Apoptosis  
Cancer  
/
HY-12041G SP600125 (GMP)
SP600125 (GMP) is SP600125 (HY-12041) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SP600125 is an orally active, reversible, and ATP-competitive JNK inhibitor with IC50s of 40, 40 and 90 nM for JNK1, JNK2 and JNK3, respectively. SP600125 is a potent ferroptosis inhibitor. SP600125 induces the transformation of bladder cancer cells from autophagy to apoptosis.
JNK   Autophagy   Apoptosis   Ferroptosis  
Bladder Cancer  
/
HY-122341 Thrazarine
Thrazarine (FR 900840) is an oncology antibiotic that can be produced by Streptomyces coerulescens MH802-fF5. Thrazarine directly inhibits DNA synthesis and tumor cell growth. Thrazarine can specifically induce lysis of tumor cells co-cultured with non-activated macrophages. Thrazarine is used in cancer research.

Source: Streptomyces sp.

Antibiotic  
/
HY-N20712 Anisomelic acid
Anisomelic acid is a human papillomavirus HPV16 E6 and HPV E7 depletor. Anisomelic acid directly interacts with HPV16 E6, promotes its ubiquitination and proteasomal degradation by recruiting E3 ubiquitin ligase, downregulates E6 and facilitates E7 degradation. Anisomelic acid induces endogenous mitochondrial apoptosis, activates caspase-3, causes cleavage of PARP, and triggers p53-independent endogenous apoptosis by depleting cIAP2. Anisomelic acid can be used in research related to HPV-positive cancers and cervical cancer.
HPV   Apoptosis   Caspase   PARP   IAP  
Cervical Cancer  
/
HY-P11104 SsrA tag
SsrA tag is an 11-aa peptide added to the C-terminus of proteins stalled during translation, targeting them for degradation by ClpXP and ClpAP.
Others  
/
HY-20457G TL8-506 (GMP)
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy.
Toll-like Receptor (TLR)   Bacterial   Interleukin Related  
Cancer   Infection   Inflammation or Immune System Disease  
/
HY-D2336 PROTAC Aster-A degrader-1
PROTAC Aster-A degrader-1 (compound NGF3) is a degrader of the sterol transport protein Aster-A. PROTAC Aster-A degrader-1 can be used as a fluorescence probe. (Red: Aster-A inhibitor, black: linker, Blue: E3 ligase ligand).
PROTACs  
Cancer  
/
HY-105463 Saptomycin D
Saptomycin D is an antibiotic with antitumor activity isolated from the Streptomyces sp. HP530 strain. Saptomycin D exhibits potent inhibitory effects against Gram-positive bacteria, while demonstrating weaker inhibitory activities against certain Gram-negative bacteria and yeasts. Saptomycin D also displays remarkable antitumor properties. Saptomycin D is applicable in research within the field of oncology.

Source: Streptomyces sp.

Antibiotic   Bacterial  
Cancer   Infection  
/
HY-169235 DHHC3 ligand 1
DHHC3 degrader 1 is a PROTAC target protein ligand that is used to synthesize PCC16 chloride (HY-169232).
Ligands for Target Protein for PROTAC  
Cancer  
/
HY-141085 Carboxyfluorescein-PEG12-NHS
Carboxyfluorescein-PEG12-NHS is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
PROTAC Linkers  
Cancer  
/
HY-P992519 PF-06940434
PF-06940434 (ADWA-11) is a monoclonal antibody targeting integrin αvβ8. PF-06940434 inhibits αvβ8-mediated TGF-β activation. PF-06940434 increases the accumulation of tumor-infiltrating CD8+ T cells and upregulates the expression of granzyme B and TNF-γ. PF-06940434 blocks the inhibitory effect of CD4+CD25+ T cells on the cytotoxic activity of tumor CD8+ T cells. PF-06940434 enhances the anti-tumor efficacy of combination therapies with other immunomodulators or radiotherapy and induces long-term anti-tumor immunity. PF-06940434 can be used in the research of squamous cell carcinoma, breast cancer, colon cancer, and prostate adenocarcinoma.
Integrin   TNF Receptor   TGF-β Receptor  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Squamous Cell Carcinoma  
/
HY-Y1804S D-Lysine-d4 monohydrochloride
D-Lysine-d4 monohydrochloride is the d4 D-Lysine monohydrochloride (HY-Y1804). D-Lysine monohydrochloride is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine monohydrochloride is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine monohydrochloride blocks renal uptake of 111In/90Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine monohydrochloride specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine monohydrochloride can be used in research related to cancer and diabetes.
Isotope-Labeled Compounds   Drug Isomer  
Cancer   Glucose Metabolism  
/
HY-D2620 CAR-2
CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LDs). CAR-2 exhibits phototoxicity in breast cancer cells with IC50 of 0.01-0.02 μM. CAR-2 exhibits antitumor efficacy in 4T1 xenograft mouse models.
Photosensitizer   Reactive Oxygen Species (ROS)   Ferroptosis  
/
HY-169232 PCC16 chloride
PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers.
PROTACs   PD-1/PD-L1  
Cancer  
/
HY-113011R Maltotriose (Standard)
Maltotriose (Standard) is the analytical standard of Maltotriose (HY-13011). This product is intended for research and analytical applications. Maltotriose is a maltooligosaccharide and a specific inducer of the Escherichia coli maltose operon. The oligosaccharide structure of Maltotriose acts as a highly efficient drug delivery carrier, which significantly enhances the targeting ability and water solubility of photosensitizers in photodynamic therapy for pancreatic cancer.
Reference Standards   Endogenous Metabolite  
/
HY-107608S1 Leukotriene B4-d5
Leukotriene B4-d5 (LTB4-d5) is deuterium labeled Leukotriene B4. Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
Isotope-Labeled Compounds   Leukotriene Receptor   PROTAC Linkers   Endogenous Metabolite  
Cancer   Inflammation or Immune System Disease  
/
HY-N15349 Nocapyrone Q
Nocapyrone Q is a polyketide compound discovered in the karst cave mold Streptomyces sp. FD-2-6. At a dose of 100 μM, Nocapyrone Q exhibits inhibitory activity against human hepatocellular carcinoma HepG2 cells and human cervical cancer HeLa cells. Nocapyrone Q holds potential for research in the field of cancer therapy.

Source: Streptomyces sp.

Others  
/
HY-163790 Desthiobiotin-PEG3-sulfo-Maleimide
Desthiobiotin-PEG3-sulfo-Maleimide is a PEG linker can be used in the synthesis of PROTACs.
PROTAC Linkers  
/
HY-W001958R Suberic acid monomethyl ester (Standard)
Suberic acid monomethyl ester (Standard) is the analytical standard of Suberic acid monomethyl ester (HY-W001958). This product is intended for research and analytical applications. Suberic acid monomethyl ester is an ester product. Suberic acid monomethyl ester is a PROTAC linker that can be used in the synthesis of PROTACs, DDD2 (HY-176261).
Biochemical Assay Reagents   PROTAC Linkers   Reference Standards  
/
HY-N16463 QS-S2
QS-S2 is the impurity of QS-21 (HY-101092A). QS-21 is an innate immune system-targeted adjuvant.
Drug Intermediate  
/
HY-140938A (Rac)-Biotin-PEG3-oxyamine hydrochloride
(Rac)-Biotin-PEG3-oxyamine hydrochloride is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
PROTAC Linkers  
Cancer  
/
HY-10984S4 Pomalidomide-13C5
Pomalidomide-13C5 (CC-4047-13C5) is 13C labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
Isotope-Labeled Compounds   Molecular Glues   Ligands for E3 Ligase   Apoptosis  
Cancer  
/
HY-A0003S3 Lenalidomide-d4
Lenalidomide-d4 (CC-5013-d4) is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
Isotope-Labeled Compounds   Ligands for E3 Ligase   Molecular Glues   Apoptosis  
Cancer   Inflammation or Immune System Disease  
/
HY-N15346 Menominin B
Menominin B is a cyclic peptide found in the freshwater sponge-associated cyanobacterium Nostoc sp. with cytotoxic properties. Menominin B exhibits antiproliferative activity against the ovarian cancer cell line OVCAR3 (with IC50 of 2.4 μM). Menominin B holds promise for research in the field of anticancer therapy.

Source: Freshwater Sponge-Associated Cyanobacterium Nostoc sp. UIC 10607

Others  
/
HY-W010041R Scyllo-Inositol (Standard)
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease.
Reference Standards   α-synuclein   Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-W034918R Docosanedioic acid (Standard)
Docosanedioic acid (Standard) is the analytical standard of Docosanedioic acid (HY-W034918). This product is intended for research and analytical applications. Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
ADC Linkers   Reference Standards   PROTAC Linkers  
/
HY-149664 3β-[N-(N′,N′-Dimethylaminoethyl)carbamoyl]cholesterol
3β-[N-(N′,N′-Dimethylaminoethyl)carbamoyl]cholesterol, a lipid, has been investigated in cancer gene therapy and vaccine delivery system.
Liposome  
Cancer  
/
HY-B0579S1 Cyclosporin A-d3
Cyclosporin A-d3 (Cyclosporine A-d3) is the deuterated-labeled Cyclosporin A (HY-B0579). Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM. Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion.
Isotope-Labeled Compounds   Molecular Glues   Complement System   Antibiotic   Cyclophilin  
Neurological, Eye or Ear Disease   Breast Cancer   Prostate Cancer   Viral Infection   Autoimmune Disease   SARS-CoV-2 Infection   Lung Fibrosis  
/
HY-D2420 Biotin-PEG5-Mal
Biotin-PEG5-Mal is a PROTAC linker, belonging to the PEG class. It can be used for the synthesis of PROTAC molecules.
PROTAC Linkers  
Cancer  
/
HY-P9S0124 Anti-CD33 Antibody (OR000283)
Anti-CD33 Antibody (OR000283) (ORM-6151 Antibody; BMS-986497 Antibody) is an antibody targeting CD33. It is generated by grafting the FAb (H&L) sequence of Gemtuzumab (HY-P99971) onto an IgG1 Fc carrying the N297A mutation, which inhibits Fc-γR binding. Anti-CD33 Antibody (OR000283) can be used to construct degrader-antibody conjugates (DACs), such as ORM-6151 (HY-171792).

Species: Human

Transmembrane Glycoprotein  
Cancer  
/
HY-24486 3-Oxopropanoic acid
3-Oxopropanoic acid is a PROTAC linker that can be used in the synthesis of PROTACs.

Source: Raja erinacea

PROTAC Linkers  
/
HY-122474 Acetylaranotin
Acetylaranotin is a metabolite produced by the fungus Arachniotus aureus, exhibiting antitumor activity. Acetylaranotin is utilized in research within the field of oncology for its potential in anti-cancer applications.

Source: Atelopus zeteki

Drug Derivative  
Cancer  
/
HY-W100287R Murrayafoline A (Standard)
Murrayafoline A (Standard) is the analytical standard of Murrayafoline A (HY-W100287). This product is intended for research and analytical applications. Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer.
NF-κB   Reference Standards   p38 MAPK   Interleukin Related   IKK   JNK   β-catenin   Wnt  
/
HY-10984S2 Pomalidomide-d4
Pomalidomide-d4 is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors<
Isotope-Labeled Compounds   Apoptosis   Molecular Glues   Ligands for E3 Ligase  
Cancer  
/
HY-141658 Pomalidomide-PEG6-C2-COOH
Pomalidomide-PEG6-C2-COOH is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide (HY-10984) based cereblon ligand and 6-unit PEG linker used in PROTAC technology.
E3 Ligase Ligand-Linker Conjugates  
Cancer  
/
HY-W248590 IR-775 chloride
IR-775 chloride is a cyanine dye with near-infrared absorption (Ex/Em = 775/795 nm). IR-775 chloride acts as a photosensitizer or photothermal agent, and induces apoptosis via generating ROS or exerting photothermal effects upon irradiation; its combination with 2-methoxyestradiol (HY-12033) inhibits SOD2 to enhance photodynamic therapy (PDT) efficacy, and its liposomal encapsulation enables phytotherapy-photothermal therapy (PTT) synergy. IR-775 chloride is applicable for investigating PDT/PTT and near-infrared fluorescence imaging in ovarian cancer and breast cancer.
Fluorescent Dye   Photosensitizer   Apoptosis   Reactive Oxygen Species (ROS)   SOD  
Breast Cancer   Ovarian Cancer  
/
HY-14658S Thalidomide-d4
Thalidomide-d4 is a deuterium labeled Thalidomide. Thalidomide inhibits cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ~250 nM, and has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties.
Molecular Glues   Ligands for E3 Ligase   Autophagy   Apoptosis  
Inflammation or Immune System Disease  
/
HY-A0003S Lenalidomide-d5
Lenalidomide-d5 is deuterium labeled Lenalidomide. Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue. Lenalidomide is an orally active immunomodulator. Lenalidomide (CC-5013) is a ligand of ubiquitin E3 ligase cereblon (CRBN), and it causes selective ubiquitination and degradation of two lymphoid transcription factors, IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase. Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
Isotope-Labeled Compounds   Ligands for E3 Ligase   Molecular Glues   Apoptosis  
Cancer   Inflammation or Immune System Disease  
/
HY-B0579S2 Cyclosporin A acetate-d4
Cyclosporin A acetate-d4 (Cyclosporine A acetate-d4) is the deuterated-labeled Cyclosporin A (HY-B0579). Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM. Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion.
Isotope-Labeled Compounds   Molecular Glues   Complement System   Antibiotic   Cyclophilin  
Neurological, Eye or Ear Disease   Breast Cancer   Prostate Cancer   Viral Infection   Autoimmune Disease   SARS-CoV-2 Infection   Lung Fibrosis  
/
HY-P11591 PDI2
PDI2 (PSMA-DOTA-PEI2) is a prostate-specific membrane antigen (PSMA) ligand that acts as a tumor retention agent, renal uptake reducer, imaging agent and antitumor agent, applicable in SPECT diagnostic imaging and radiotheranostics. PDI2 specifically binds to PSMA on prostate cancer cells, enters cells via clathrin-dependent endocytosis, and exhibits higher tumor retention rate and lower renal uptake level. PDI2 is applicable in research related to prostate cancer and castration-resistant metastatic prostate cancer.
Radionuclide-Drug Conjugates (RDCs)   PSMA  
Prostate Cancer  
/
HY-140696D m-PEG10000-OH
m-PEG10000-OH (mPEG10000-Hydroxy; Polyethylene glycol monomethyl ether 10000) is a hydroxyl-terminated methoxylated polyethylene glycol (PEG-based) compound that serves as a linker for PROTACs. m-PEG10000-OH is applicable to research on healthcare-associated infections.
Environmental Pollutants   PROTAC Linkers  
Infection  
/
HY-140956 DSPE-PEG8-Mal
DSPE-PEG8-Mal is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.
Liposome   PROTAC Linkers  
Cancer  
/
HY-180989 PROTAC PLK1 Degrader-2
PROTAC PLK1 Degrader-2 is a peptide-based N-end rule PLK1 mini-PROTAC. PROTAC PLK1 Degrader-2 utilizes Arg12 as dual-function cell-permeable N-degron to recruit UBR1/UBR2 E3 ligases, mediates PLK1 ubiquitination and proteasome-dependent degradation. PROTAC PLK1 Degrader-2 suppresses cervical cancer cell proliferation, induces G2/M cell cycle arrest and tumor cell apoptosis, and exerts potent in vivo anti-tumor efficacy in mice and can be applied to research on PLK1-driven cervical carcinoma.
PROTACs   Polo-like Kinase (PLK)   Apoptosis   Ligands for E3 Ligase  
Cervical Cancer  
/
HY-P991689 Girancitug
Girancitug is a humanized IgG1κ monoclonal antibody inhibitor targeting VEGFR2/KDR/CD309. Girancitug effectively inhibits angiogenesis. Girancitug can be used for anti-angiogenic therapy in cancers like colorectal and ovarian cancer research.

Species: Human

VEGFR  
Cancer  
/
HY-P11280A PRAME peptide (425-433) acetate
PRAME peptide (425-433) acetate is a proteasome-degraded peptide derived from the cancer-testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). PRAME peptide (425-433) acetate is restricted by HLA-A*02:01 and can serve as a target for bispecific T cell engager therapy in the context of major histocompatibility complex I presentation. PRAME peptide (425-433) acetate shows application potential in various malignant tumors and is widely suitable for research related to solid tumors, melanoma, ovarian cancer, endometrial cancer, and lung cancer (including lung adenocarcinoma and lung squamous cell carcinoma). PRAME peptide (425-433) acetate can be used to explore disease of triple-negative breast cancer, diffuse large B-cell lymphoma, and head and neck squamous cell carcinoma.
Melanocortin Receptor  
Breast Cancer   Leukemia/Lymphoma/Myeloma   Ovarian Cancer   Lung Squamous Cell Carcinoma   Squamous Cell Carcinoma  
/
HY-10984S3 Pomalidomide-15N,13C5
Pomalidomide-15N,13C5 is 15N and 13C labeled Pomalidomide (HY-10984). Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
Molecular Glues   Ligands for E3 Ligase   Apoptosis   Isotope-Labeled Compounds  
Cancer  
/
HY-P5931 Spinoxin
Spinoxin isolated from the venom of scorpion Heterometrus spinifer, is a 34-residue peptide neurotoxin cross-linked by four disulfide bridges. Spinoxin is a potent inhibitor of Kv1.3 potassium channel (IC50 = 63 nM), considering to be valid molecular targets in the diagnostics and therapy of various autoimmune disorders and cancers.
Potassium Channel  
Cancer   Inflammation or Immune System Disease  
/
HY-A0023AS2 Alogliptin-13C,d3 benzoate
Alogliptin-13C,d3 (SYR-322-13C,d3) benzoate is deuterium labeled Alogliptin Benzoate (HY-A0023). Alogliptin Benzoate (SYR-322) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of <10 nM, and exhibits greater than 10,000-fold selectivity over DPP-8 and DPP-9. Alogliptin Benzoate can be used for the research of type 2 diabetes.
Isotope-Labeled Compounds   Dipeptidyl Peptidase   Ferroptosis  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Type 2 Diabetes  
/
HY-N9968 Cucurbitacin C
Cucurbitacin C is a tetracyclic triterpenoid compound. Cucurbitacin C exhibits significant in vivo and in vitro anticancer activity, which inhibits the PI3K/AKT signaling pathway to induce cell cycle arrest and apoptosis in cancer cells, and significantly suppresses the growth of HepG2 and PC-3 xenograft tumors in mice. Cucurbitacin C can be used in studies on plant defense mechanisms, secondary metabolism and cancer therapy.
Akt   Apoptosis  
Cancer  
/
HY-W035399S D-Lysine-d8 dihydrochloride
D-Lysine-d8 dihydrochloride is the d8-labeled D-Lysine (HY-Y1091). D-Lysine is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine blocks renal uptake of 111In/90Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine can be used in research related to cancer and diabetes.
Isotope-Labeled Compounds   Drug Isomer  
Cancer   Glucose Metabolism  
/
HY-W1124386 BG-DBCO
BG-DBCO (SNAP-DBCO) is a key bifunctional reagent that acts as a "bridge" in the ClickRNA-PROTAC system. BG-DBCO possesses a SNAPTag covalent anchoring handle and a copper-free click chemistry handle: one end covalently locks SNAPTag fusion proteins via BG, while the other end captures azide-modified target protein ligands through copper-free click chemistry (SPAAC), thereby assembling the "exogenous E3 fusion protein" and "POI ligand" into a complete PROTAC ternary complex in living cells.
Biochemical Assay Reagents  
/
HY-P990716 Sabestomig
Sabestomig (AZD7789) is a monovalent bispecific antibody targeting PD-1 and TIM-3. Sabestomig binds to PD-1 and an epitope in the TIM-3 IgV domain outside the phosphatidylserine-binding cleft, thereby precisely regulating immune responses. Sabestomig promotes IL-2 production, efferocytosis and cross-presentation of tumor antigens, and enhances the release of anti-tumor T cell cytokines, cytotoxicity, and secretion of IFN-γ. Sabestomig inhibits the growth of solid tumors, prolongs the duration of tumor suppression, and significantly enhances anti-tumor responses following anti-PD-1 therapy. Sabestomig has been used in studies related to non-small cell lung cancer and classical Hodgkin lymphoma.

Species: Human

PD-1/PD-L1   Tim3  
Inflammation or Immune System Disease  
/
HY-B0633E Hyaluronic acid, low endotoxin
Hyaluronic acid, low endotoxin (Hyaluronan, low endotoxin) is a biopolymer composed of repeating disaccharide units containing low levels of endotoxin. Hyaluronic acid is a major component of the extracellular matrix (ECM). It is synthesized on the plasma membrane. Hyaluronic acid exerts its effects by binding to receptors CD44 and RHAMM. Hyaluronic acid activates PI3K-Akt signaling. Hyaluronic acid also enhances cell invasion and angiogenesis by promoting or stimulating the binding of proteolytic MMP-9 to the cell surface. Elevated hyaluronic acid levels are associated with tumor cell growth, adhesion, migration, invasion, and angiogenesis in digestive system cancers. Hyaluronic acid is involved in tissue remodeling and rapid cell proliferation in several physiological processes, including embryonic morphogenesis and wound healing. Hyaluronic acid can be used as a regulator of cancer-associated lymphangiogenesis. Hyaluronic acid can be used as a drug delivery carrier for sodium butyrate, enhancing its anti-proliferative activity against breast cancer cell lines. Hyaluronic acid can lubricate the corneal endothelium. Hyaluronic acid can improve tissue hydration and enhance the resistance of cells to mechanical damage. Hyaluronic acid has been conjugated with antibodies to ensure that the active compound continues to exert its effects at the site of inflammation. Hyaluronic acid can be used in research in the fields of osteoarthritis, ophthalmology, cosmetic dermatology, oncology, and liver diseases.
Endogenous Metabolite   CD44   Bacterial   Akt   PI3K  
Cancer   Inflammation or Immune System Disease   Visual System Disease   Liver Disease   Osteoarthritis  
/
HY-P11228 FPP29
FPP29 is a potent peptide-based FOXM1 PROTAC degrader. FPP29 induces ubiquitination and degradation of FOXM1. FPP29 inhibits FOXM1 via the ubiquitin-proteasome degradation pathway. FPP29 induces Apoptosis. FPP29 suppresses tumor growth in hepatocellular carcinoma xenograft models. FPP29 can be used in the research of hepatocellular carcinoma (cell-penetrating peptide: (HY-P0133); VHL ligase ligand: (HY-P11493); linker: (HY-W013664); FOXM1 ligand: (HY-P11494)).
PROTACs   FOXM1   Apoptosis   DNA/RNA Synthesis  
Liver Cancer  
/
HY-P99668 Iparomlimab
Iparomlimab is an anti-human PD-1/CD279/PDCD1 IgG4κ antibody. Iparomlimab also targets to human monoclonal PSB103 γ4-chain, disulfided with human monoclonal PSB103 κ-chain to form a dimer. Iparomlimab can be used for Oncology research.

Species: Human

PD-1/PD-L1  
Cancer  
/
HY-P10446 TAT-PiET-PROTAC
TAT-PiET-PROTAC is a proteolysis-targeting chimera (PROTAC)-modified TAT-PiET (HY-P10445), which is a cell-penetrating peptide targeting the extra-terminal (ET) domain of BRD4. TAT-PiET-PROTAC can reduce BRD4 and JMJD6 levels and inhibit cell proliferation. TAT-PiET-PROTAC also resists the endocrine resistance of ERα-positive breast cancer cells. TAT-PiET-PROTAC can be used for the research of cancer, such as breast cancer.
Epigenetic Reader Domain   PROTACs  
/
HY-10984S1 Pomalidomide-d3
Pomalidomide-d3 is the deuterium labeled Pomalidomide. Pomalidomide, the third-generation immunomodulatory agent, acts as molecular glue. Pomalidomide interacts with the E3 ligase cereblon and induces degradation of essential Ikaros transcription factors.
Ligands for E3 Ligase   Molecular Glues   Apoptosis  
Cancer  
/
HY-W034918 Docosanedioic acid
Docosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Docosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
ADC Linkers   PROTAC Linkers  
Cancer  
/
HY-N0170R Indole-3-carbinol (Standard)
Indole-3-carbinol (Standard) is the analytical standard of Indole-3-carbinol. This product is intended for research and analytical applications. Indole-3-carbinol (I3C) inhibits NF-κB activity and also is an Aryl hydrocarbon receptor (AhR) agonist, and an inhibitor of WWP1 (WW domain-containing ubiquitin E3 ligase 1).
NF-κB   Aryl Hydrocarbon Receptor   E1/E2/E3 Enzyme   Endogenous Metabolite   Reference Standards  
Cancer  
/
HY-W024365 3-tert-Butyl-4-methoxyphenol
3-tert-Butyl-4-methoxyphenol is a PROTAC linker, belongs to alkyl/ether class, with insecticidal activity. 3-tert-Butyl-4-methoxyphenol also induced increased activities of glutathione (GSH) S-transferase and epoxide hydrolase in the liver and forestomach tissues of A/HeJ mice, regulating the carcinogen metabolism system.
PROTAC Linkers  
Cancer  
/
HY-176785S MCB-294
MCB-294 is a dual-state pan-KRAS inhibitor that selectively inhibits KRAS over NRAS and HRAS. MCB-294 capable of binding both the active (GTP-bound) and inactive (GDP-bound) forms of KRAS with Kds of approximately 1 pM and 10 nM, respectively. MCB-294 broadly impairs the growth of hTERT-HPNE cells expressing G12D, G12C, G12V, G12S, G13D, and wild-type KRAS, with IC50s of approximately 700 nM. MCB-294 induces irreversible apoptosis in KRAS-mutated tumors. MCB-294 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-294 can be used for the study of pancreatic cancer, colorectal cancer and lung cancer.
Ras   Apoptosis   p38 MAPK   Caspase   TNF Receptor  
/
HY-P99830 Conbercept
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC50 = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (Kd = 0.5 pM), VEGF-B (Kd = 8 pM), VEGF-C, and PlGF (Kd = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV).
VEGFR   TNF Receptor   Interleukin Related  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Breast Cancer  
/
HY-W013664 Glycyl-l-serine
Glycyl-l-serine is a PROTAC linker composed of glycine and serine. Glycyl-l-serine can be used in the synthesis of PROTACs, such as FPP29 (HY-P11228).
PROTAC Linkers  
Cancer  
/
HY-W440886 DSPE-PEG3400-Biotin
DSPE-PEG3400-Biotin is a phospholipid PEG for biotinylation. The amphiphilic property of the DSPE-PEG is useful for precision drug delivery and cancer therapy.
Liposome  
Cancer  
/
HY-10219GL Rapamycin (GMP Like)
Rapamycin (Sirolimus) GMP Like is Rapamycin (HY-10219) produced by using GMP like guidelines. GMP Like small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin is a molecular glue that binds FKBP12 and mTOR proteins together, thereby inhibiting mTOR kinase activity. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant.
mTOR   FKBP   Molecular Glues   Fungal   Autophagy   Endogenous Metabolite   Antibiotic   Bacterial  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Fungal Infection   Pain   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
/
HY-N10568 Gibberellin A9
Gibberellin A9 is a plant hormone that targets gibberellin receptor GID1. Gibberellin A9 binds to GID1 to form a GA-GID1-DELLA protein complex, which promotes the degradation of DELLA proteins. This relieves the inhibitory effect of DELLA proteins on plant growth, thereby promoting plant cell elongation and division, and increasing seed germination rate. Gibberellin A9 is promising for use in studies on plant growth and development, such as stem elongation and flowering induction.
Phytohormone  
/
HY-P11498 Cyclomarin monomer-2
Cyclomarin monomer-2 (Compound 10), a cyclomarin monomer, is a pre-dimerization precursor that can form Homo-BacPROTACs targeting the degradation of ClpC1. Cyclomarin monomer-2 binds to the Mtb ClpC1 protein with a KD of 4.0 nM. The MIC of Cyclomarin monomer-2 against the Mtb H37Rv standard strain is 3.1 μM. Cyclomarin monomer-2 can be used as a key intermediate in the development of Homo-BacPROTACs.
Drug Intermediate   Bacterial  
Mycobacterium Tuberculosis Infection  
/
HY-W105740 12-Aminododecanoic acid
12-Aminododecanoic acid is a PROTAC linker.
PROTAC Linkers   Amino Acid Derivatives  
/
HY-136158A 6-Maleimidocaproic acid sulfo-NHS sodium
6-Maleimidocaproic acid sulfo-NHS (Sulfo-EMCS) sodium is an alkyl/ether-based PROTAC linker that can be used in the synthesis of PROTACs.
PROTAC Linkers  
Cancer  
/
HY-P10412 A11
A11 (ANXA1-derived 11 amino acid-long peptide) is a ANXA1-EphA2 interaction-blocking peptide. A11 reduces ANXA1 bound to EphA2 and increases Cbl (the E3 ubiquitin ligase of EphA2) bound to EphA2. A11 inhibits the proliferation, migration and invasion of nasopharyngeal carcinoma cells. A11 inhibits angiogenesis. A11 can be used in studies related to nasopharyngeal carcinoma.
Ephrin Receptor   Annexin A  
Cancer  
/
HY-W008951 Ethylenediaminetetra(methylenephosphonic acid)
Ethylenediaminetetramethylenephosphonic acid (EDTMP) is a bone-targeted chelating agent. Ethylenediaminetetramethylenephosphonic acid sodium‘s phosphonic acid groups possess a unique ability to bind with high affinity to hydroxyapatite in bone, and can form radioactive compounds with 153Sm and 177Lu. Ethylenediaminetetramethylenephosphonic acid is used to study palliative therapy for pain associated with multiple bone metastatic cancers.
Radionuclide-Drug Conjugates (RDCs)  
Pain   Multiple Myeloma  
/
HY-N2991 Dehydropachymic acid
Dehydropachymic acid is one of the major triterpenes isolated from Poria cocos. Dehydropachymic acid is more effective in autophagy-lysosome pathway (ALP) impaired cells rather than normal cells.
Autophagy  
Neurological, Eye or Ear Disease  
/
HY-P11497 Cyclomarin monomer-1
Cyclomarin monomer-1 (Compound 5), a cyclomarin monomer, is a pre-dimerization precursor that can form Homo-BacPROTACs targeting the degradation of ClpC1. Cyclomarin monomer-1 binds to the Mtb ClpC1 protein with a KD of 3.5 nM. The MIC of Cyclomarin monomer-1 against the Mtb H37Rv standard strain is 1.6 μM. Cyclomarin monomer-1 can be used as a key intermediate in the development of Homo-BacPROTACs.
Drug Intermediate   Bacterial  
Mycobacterium Tuberculosis Infection  
/
HY-153039 Anhydroleucovorin
Anhydroleucovorin is a form of tetrahydrofolate and serves as a substrate for cyclohydrolase, which converts it to 10-formyltetrahydrofolate. Anhydroleucovorin can be used in oncology research.
Drug Intermediate  
Cancer  
/
HY-W088475 Undec-10-yn-1-ol
Undec-10-yn-1-ol is a PROTAC linker that can be used in the synthesis of PROTACs.
PROTAC Linkers  
/
HY-101092A QS-21
QS-21 is a mixture of QS-21-Xyl (HY-101092B) and QS-21-Api (HY-101092), with a ratio of 35:65. QS-21 is an innate immune system-targeted adjuvant. QS-21 is promising for research of oncology vaccines (e.g., melanoma) and infectious disease vaccines (e.g., HIV, malaria).
Toll-like Receptor (TLR)  
Cancer   Infection  
/
HY-107608S Leukotriene B4-d4
Leukotriene B4-d4 is the deuterium labeled Leukotriene B4. Leukotriene B4 (LTB4) is known as one of the most potent chemoattractants and activators of leukocytes and is involved in inflammatory diseases. Leukotriene B4 is also an alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs.
Endogenous Metabolite   PROTAC Linkers   Leukotriene Receptor  
Cancer   Inflammation or Immune System Disease  
/
HY-W023573 5-Aminothalidomide
5-Aminothalidomide is an E3 ligase ligand used in PROTAC technology. 5-Aminothalidomide can be used to synthesize various PROTACs, such as the PROTAC BRD9 Degrader-7 (HY-155361).
Ligands for E3 Ligase  
Cancer  
/
HY-P5285 Lunasin
Lunasin is a bioactive peptide with antioxidant, anti-inflammatory, anticancer and anti-aging properties. Lunasin can be isolated from soybean. Lunasin also has an epigenetic mechanism of action associated with histone acetylation. Lunasin can be internalized into cells and inhibit Oncosphere formation in cancer cells.
Parasite  
Infection   Inflammation or Immune System Disease  
/
HY-Y1091 D-Lysine
D-Lysine is the D-enantiomer of L-Lysine (HY-N0469). D-Lysine is metabolically inert and not utilized for protein synthesis by mammalian ribosomes. D-Lysine blocks renal uptake of 111In/90Y-Octreotide (HY-P0036)-based probes without inhibiting uptake by tumor/receptor tissues, and thus acts as a renoprotective agent in diagnostic imaging and peptide receptor radionuclide therapy (PRRT). D-Lysine specifically inhibits the early steps of non-enzymatic glycation by competing with glucose via its free amino group, theoretically, it can serve as a glycation competitor that "does not interfere with protein synthesis" under chronic hyperglycemia in diabetes. D-Lysine can be used in research related to cancer and diabetes.
Drug Isomer  
Cancer   Glucose Metabolism  
/
HY-W013021 Norbornene
Norbornene is a cycloolefin and building block for synthesis of porous organic polymeric materials via metathesis, addition, and CANAL polymerization. Norbornene can also be used as an E3 ligase ligand for the synthesis of PROTAC, such as PROTAC HyTTD Degrader-1 (HY-181895).
Ligands for E3 Ligase  
/
HY-W100287 Murrayafoline A
Murrayafoline A is a carbazole alkaloid that can be extracted from Murraya tetramera. Murrayafoline A directly targets Specificity protein 1 (Sp1), thereby inhibiting NF-κB and MAPK signaling pathways. Murrayafoline a induces a G0/G1-phase arrest in platelet-derived growth factor (PDGF)-stimulated vascular smooth muscle cells. Murrayafoline A attenuates the Wnt/β-catenin pathway by promoting the degradation of intracellular β-catenin proteins. Murrayafoline A enhances the contraction of rat ventricular myocytes and L-type calcium current by activating protein kinase C. Murrayafoline A inhibits LPS (HY-D1056)-induced neuroinflammation in vivo. Murrayafoline A can be used for the study of inflammation, vascular complications and colon cancer.
NF-κB   p38 MAPK   Interleukin Related   IKK   JNK   β-catenin   Wnt  
Lung Cancer   Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Parkinson's Disease   Hypertension   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
/
HY-13756R Tacrolimus (Standard)
Tacrolimus (Standard) (FK506 (Standard); Fujimycin (Standard); FR900506 (Standard)) is the analytical standard of Tacrolimus (HY-13756). This product is intended for research and analytical applications. Tacrolimus (FK506), a molecular glue, a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.
Reference Standards   Phosphatase   FKBP   Molecular Glues   Bacterial   Autophagy   Antibiotic  
Inflammation or Immune System Disease  
/
HY-N0140R Ursolic acid (Standard)
Ursolic acid (Standard) is the analytical standard of Ursolic acid. This product is intended for research and analytical applications. Ursolic acid (Prunol) is a natural pentacyclic triterpenoid carboxylic acid, exerts anti-tumor effects and is an effective compound for cancer prevention and therapy.
Reference Standards   Autophagy   Endogenous Metabolite  
Cancer  
/
HY-N2500 Deoxypodophyllotoxin
Deoxypodophyllotoxin (DPT), a derivative of podophyllotoxin, is a lignan with potent antimitotic, anti-inflammatory and antiviral properties isolated from Anthriscus sylvestris. Deoxypodophyllotoxin, targets the microtubule, has a major impact in oncology not only as anti-mitotics but also as potent inhibitors of angiogenesis. Deoxypodophyllotoxin induces cell autophagy and apoptosis. Deoxypodophyllotoxin evokes increase of intracellular Ca2+ concentrations in DRG neurons.
Microtubule/Tubulin   Apoptosis   Autophagy  
Infection   Digestive System Disease   Lung Cancer   Digestive System Inflammation   Cardiovascular Disease   Obesity  
/
HY-P990059 Puxitatug
Puxitatug (INT-016; AZD8205 Antibody) is a monoclonal antibody targeting VTCN1/B7-H4. Puxitatug can be used to synthesize antibody-drug conjugates (ADCs), such as Puxitatug samrotecan (HY-171689), which can be applied to various solid tumors. Puxitatug can also be used for researching adjuvant therapies for gastric cancer.

Species: Human

ADC Antibodies   CD276/B7-H3  
Cancer  
/
HY-W010041 Scyllo-Inositol
Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease.
α-synuclein   Amyloid-β  
Alzheimer's Disease   Parkinson's Disease   Lung Fibrosis  
/
HY-W034595 Eicosanedioic acid
Eicosanedioic acid is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Eicosanedioic acid is also a alkyl chain-based PROTAC linker that can be used in the synthesis
ADC Linkers   PROTAC Linkers  
Cancer  
/
HY-B0579R Cyclosporin A (Standard)
Cyclosporin A (Standard) (Cyclosporine A (Standard)) is the analytical standard of Cyclosporin A (HY-B0579). This product is intended for research and analytical applications. Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of protein phosphatase 2B (PP2B/calcineurin) with an IC50 of 5 nM. Cyclosporin A is a molecular glue, binds to cyclophilin and calcineurin, leading to inactivation of nuclear Factor of activated T Cells (NFAT) and a subsequent decrease in the immune response. Cyclosporin A also inhibits CD11a/CD18 adhesion.
Reference Standards   Molecular Glues   Complement System   Antibiotic   Cyclophilin  
Neurological, Eye or Ear Disease   Breast Cancer   Prostate Cancer   Viral Infection   Autoimmune Disease   SARS-CoV-2 Infection   Lung Fibrosis  
/
HY-P99038 Odronextamab
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research.

Species: Human

CD20   CD3  
Leukemia/Lymphoma/Myeloma  
/
HY-10219R Rapamycin (Standard)
Rapamycin (Standard) (Sirolimus (Standard)) is the analytical standard of Rapamycin (HY-10219). This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific blood-brain barrier-transmissible mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin is a molecular glue that binds FKBP12 and mTOR proteins together, thereby inhibiting mTOR kinase activity. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant.
Reference Standards   mTOR   FKBP   Molecular Glues   Fungal   Autophagy   Endogenous Metabolite   Antibiotic   Bacterial  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Bacterial Infection   Fungal Infection   Pain   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
/
HY-W087830 L-p-Boronophenylalanine
L-p-Boronophenylalanine is a boron-containing substrate for L-type amino acid transporters (LAT1 and LAT2). L-p-Boronophenylalanine enters tumor cells by competing with natural amino acids for LAT, selectively accumulating boron in cancer cells. L-p-Boronophenylalanine can be used in boron neutron capture therapy (BNCT). When boron-10 captures thermal neutrons, a nuclear reaction occurs, producing high-energy alpha particles and lithium nuclei, which kill cancer cells at close range with little damage to surrounding tissues. L-p-Boronophenylalanine can be used in cancer research, especially glioblastoma and anaplastic astrocytoma.
Biochemical Assay Reagents  
Cancer  
/
HY-P99896 Runimotamab
Runimotamab (BTRC-4017A) is a HER2 and CD3 T cell-engaging bispecific antibody. Runimotamab can decrease the size of liver tumor spheroids. Runimotamab can be studied in oncology research such as HER2-expressing cancers. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

EGFR   CD3  
Cancer  
/
HY-W020780 mPEG5000-Mal
mPEG5000-Mal (mPEG5000-Maleimide) is a PEG-derived selective covalent binding agent for sulfhydryl groups (RSGs), which can form irreversible thioether bonds with sulfhydryl groups under near-neutral conditions via the maleimide group. The mechanism of action of mPEG5000-Mal can be divided into two categories: firstly, as an enzyme modifier, it binds to target proteins through hydrophobic interactions, hydrogen bonds, and van der Waals forces, altering the protein's secondary structure; secondly, as a nanoparticle surface modifier, it covalently binds to sulfhydryl groups on the surface of red blood cells, changing the surface properties and morphology of the red blood cells, leading to their phagocytosis by macrophages of the reticuloendothelial system. mPEG5000-Mal can react with free cysteine in proteins, increasing the apparent molecular weight of the modified protein by 10-15 kDa for detection purposes. mPEG5000-Mal can enhance the thermal stability and catalytic activity of enzymes, and improve the macrophage targeting of nanoparticles, enabling targeted drug delivery. mPEG5000-Mal can be applied in enzyme engineering research in the food industry and in oncology, assisting radiotherapy by inhibiting tumor-associated macrophage infiltration and enhancing anti-tumor immune responses.
Biochemical Assay Reagents  
/
HY-100355 C18-Ceramide (d18:1/18:0)
C18-Ceramide (d18:1/18:0) is a bioactive molecule with multiple functions in cells, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology.
Endogenous Metabolite  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P701595 NEDD4L Protein, Human
The NEDD4L protein is an E3 ubiquitin protein ligase that regulates multiple signaling pathways, including autophagy, innate immunity, and DNA repair. NEDD4L Protein, Human is the recombinant human-derived NEDD4L protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

Enzymes & Regulators Ubiquitin Related Proteins Transferases (EC 2) Ubiquitin Enzymes E3 Ligases

/
HY-P701596 NEDD4L Protein, Human (His)
The NEDD4L protein is an E3 ubiquitin protein ligase that regulates multiple signaling pathways, including autophagy, innate immunity, and DNA repair. NEDD4L Protein, Human (His) is the recombinant human-derived NEDD4L protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Ubiquitin Related Proteins Transferases (EC 2) Ubiquitin Enzymes E3 Ligases

/
HY-P75894A ITCH/AIP4 Protein, Human
ITCH/AIP4 protein is an E3 ubiquitin protein ligase that catalyzes the conjugation of “Lys-29”, “Lys-48” and “Lys-63” linked ubiquitin, affecting inflammatory signaling pathways. It forms a ubiquitin editing complex that promotes RIPK1 degradation and terminates TNF- or LPS-mediated NFKB1 activation. ITCH/AIP4 Protein, Human is the recombinant human-derived ITCH/AIP4 protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

Ubiquitin Related Proteins Ubiquitin Enzymes E3 Ligases ITCH Proteins

/
HY-P701512 SMURF2 Protein, Human (His)
SMURF2 protein is an E3 ubiquitin protein ligase that interacts with SMAD7 to induce ubiquitin-dependent degradation of TGF-β receptors and downregulate TGF-β signaling. This interaction triggers autocatalytic degradation of SMURF2 and is antagonized by AIMP1. SMURF2 Protein, Human (His) is the recombinant human-derived SMURF2 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Ubiquitin Related Proteins Transferases (EC 2) Ubiquitin Enzymes E3 Ligases

/
HY-P75894 ITCH/AIP4 Protein, Human (solution)
ITCH/AIP4 Protein, Human (solution) is the recombinant human-derived ITCH/AIP4 protein, expressed by E. coli, with tag free tag.

Species: Human; Source: E. coli

Ubiquitin Related Proteins Ubiquitin Enzymes E3 Ligases ITCH Proteins

/
HY-P701526 HACE1 Protein, Human (His)
The HACE1 protein is an E3 ubiquitin protein ligase that regulates Golgi membrane fusion and small GTPases. HACE1 Protein, Human (His) is the recombinant human-derived HACE1 protein, expressed by E. coli , with N-6*His labeled tag.

Species: Human; Source: E. coli

Enzymes & Regulators Ubiquitin Related Proteins Transferases (EC 2) Ubiquitin Enzymes E3 Ligases

/
HY-P7S1176 MARCH9 Protein, Mouse (Cell-Free, His)

Species: Mouse; Source: E. coli Cell-free

/
HY-P701513 SMURF2 Protein, Human
SMURF2 protein is an E3 ubiquitin protein ligase that interacts with SMAD7 to induce ubiquitin-dependent degradation of TGF-β receptors and downregulate TGF-β signaling. This interaction triggers autocatalytic degradation of SMURF2 and is antagonized by AIMP1. SMURF2 Protein, Human is the recombinant human-derived SMURF2 protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

Enzymes & Regulators Ubiquitin Related Proteins Transferases (EC 2) Ubiquitin Enzymes E3 Ligases

/
HY-P702075 PELI2 Protein, Human
PELI2 protein is an E3 ubiquitin ligase that links ubiquitin to substrate proteins. PELI2 Protein, Human is the recombinant human-derived PELI2 protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

Enzymes & Regulators Ubiquitin Related Proteins Transferases (EC 2) Ubiquitin Enzymes E3 Ligases

/
HY-P701522 DTX3 Protein, Human
The DTX3 protein is a multifunctional regulator of Notch signaling that regulates intercellular communication and cell fate decisions. Its effects are context-dependent, exhibiting positive and negative regulation depending on the developmental and cellular environment. DTX3 Protein, Human is the recombinant human-derived DTX3 protein, expressed by E. coli , with tag free.

Species: Human; Source: E. coli

Enzymes & Regulators Ubiquitin Related Proteins Transferases (EC 2) Ubiquitin Enzymes E3 Ligases

/
HY-P87078 SMURF1 Antibody (YA6771)
SMURF1 Antibody (YA6771) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SMURF1.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P811087 SIAH2 Antibody
SIAH2 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to SIAH2.

Host: Rabbit; Reactivity: Human, Mouse, Rat, Zebrafish

Polyclonal Antibodies Primary Antibodies

/
HY-P89595 TRIM37 Antibody (YA8939)
TRIM37 Antibody (YA8939) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to TRIM37.

Host: Mouse; Reactivity: human, mouse, rat

Monoclonal Antibodies Primary Antibodies

/
HY-P810024 Ubr3 Antibody (YA9368)
Ubr3 Antibody (YA9368) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Ubr3.

Host: Mouse; Reactivity: human, mouse, rat

Monoclonal Antibodies Primary Antibodies

/
HY-P811462 TRIM36 Antibody
TRIM36 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to TRIM36.

Host: Rabbit; Reactivity: Human, Mouse

Polyclonal Antibodies Primary Antibodies

/
HY-P811621 PJA2 Antibody
PJA2 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to PJA2.

Host: Rabbit; Reactivity: Human

Polyclonal Antibodies Primary Antibodies

/
HY-P87190 SIAH1 Antibody (YA6878)
SIAH1 Antibody (YA6878) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to SIAH1.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Flow Cytometry Antibodies Primary Antibodies

/
HY-P89585 TOPORS Antibody (YA8929)
TOPORS Antibody (YA8929) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to TOPORS.

Host: Mouse; Reactivity: human

Monoclonal Antibodies Primary Antibodies

/
HY-P810969 PIAS3 Antibody
PIAS3 Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to PIAS3.

Host: Rabbit; Reactivity: Human, Mouse, Rat, Pig, Dog, Bovine

Polyclonal Antibodies Primary Antibodies

/
HY-P811074 IDOL Antibody
IDOL Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to IDOL.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Polyclonal Antibodies Primary Antibodies

/
HY-K0002 Bacterial Protein Extraction Reagent

MCE Bacterial Protein Extraction Reagent integrates both lysozyme and nuclease activities and is specifically formulated for E. coli lysis. It efficiently disrupts the peptidoglycan layer under mild conditions to rapidly release intracellular proteins. Simultaneously, the incorporated nucleases degrade genomic DNA/RNA, significantly reducing lysate viscosity and minimizing nucleic-acid interference, thereby preserving the native conformation and functional integrity of target proteins to the greatest extent.

Protein Biology Protein Sample Preparation Cell Lysis

/

References

[1]. Dale B, et al. Advancing targeted protein degradation for cancer therapy. Nat Rev Cancer. 2021;21(10):638-654.  [Content Brief]

[2]. Kong NR, et al. Clinical translation of targeted protein degraders. Clin Pharmacol Ther. 2023;114(3):558-569.  [Content Brief]

[3]. Brodermann MH, et al. The emerging role of targeted protein degradation to treat and study cancer. J Pathol. 2024;263(2):125-138.  [Content Brief]

[4]. Cassidy K, et al. Redefining the scope of targeted protein degradation: translational opportunities in hijacking the autophagy-lysosome pathway. Biochemistry. 2021;60(25):1961-1974.  [Content Brief]

[5]. Qin L, et al. Key considerations in targeted protein degradation drug discovery and development. Front Chem. 2022;10:934337.  [Content Brief]

[6]. Thomas E, et al. Targeted degradation of androgen receptor by VNPP433-3β in castration-resistant prostate cancer cells implicates interaction with E3 ligase MDM2 resulting in ubiquitin-proteasomal degradation. Cancers (Basel). 2023;15(4):1198.  [Content Brief]

[7]. Sasso JM, et al. Molecular glues: the adhesive connecting targeted protein degradation to the clinic. Biochemistry. 2023;62(4):601-623.  [Content Brief]

[8]. Dai M, et al. Targeted protein degradation: an important tool for drug discovery for “undruggable” tumor transcription factors. Technol Cancer Res Treat. 2022;21:15330338221095950.  [Content Brief]

[9]. Kim H, et al. Targeted protein degradation to overcome resistance in cancer therapies: PROTAC and N-degron pathway. Biomedicines. 2022;10(9):2100.  [Content Brief]

Keywords

targeted protein degradation | PROTAC | molecular glue | ubiquitin-proteasome system | E3 ligase | autophagy-lysosome pathway | cancer therapy | undruggable targets | precision oncology